Scott B. Patten

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2332858/publications.pdf

Version: 2024-02-01

797 117,829 101
papers citations h-index

829 829 829 140552 all docs docs citations times ranked citing authors

320

g-index

#	Article	IF	CITATIONS
1	Association Between Excess Sleep Duration and Risk of Stroke: A Population-Based Study. Canadian Journal of Neurological Sciences, 2023, 50, 17-22.	0.3	3
2	The impact of the <scp>COVID</scp> â€19 pandemic on eating disorders: A systematic review. International Journal of Eating Disorders, 2023, 56, 5-25.	2.1	127
3	Validating the Mild Behavioral Impairment Checklist in a Cognitive Clinic: Comparisons With the Neuropsychiatric Inventory Questionnaire. Journal of Geriatric Psychiatry and Neurology, 2023, 36, 107-120.	1.2	28
4	Psychological characteristics and childhood adversity of adolescents with atypical anorexia nervosa versus anorexia nervosa. Eating Disorders, 2022, 30, 210-222.	1.9	19
5	Does providing personalized depression risk information lead to increased psychological distress and functional impairment? Results from a mixed-methods randomized controlled trial. Psychological Medicine, 2022, 52, 2071-2079.	2.7	8
6	Comparison of different scoring methods based on latent variable models of the PHQ-9: an individual participant data meta-analysis. Psychological Medicine, 2022, 52, 3472-3483.	2.7	9
7	Increasing Rates of Youth and Adolescent Suicide in Canadian Women. Canadian Journal of Psychiatry, 2022, 67, 67-69.	0.9	1
8	Considering a risk profile based on emergency department utilization in young people with eating disorders: Implications for early detection. International Journal of Eating Disorders, 2022, 55, 1219-1228.	2.1	4
9	"Teachers Often See the Red Flags First― Perceptions of School Staff Regarding Their Roles in Supporting Students with Mental Health Concerns. School Mental Health, 2022, 14, 402-415.	1.1	21
10	Childhood Maltreatment and Psychiatric Comorbidity in Immune-Mediated Inflammatory Disorders. Psychosomatic Medicine, 2022, 84, 10-19.	1.3	15
11	External validation of a shortened screening tool using individual participant data meta-analysis: A case study of the Patient Health Questionnaire-Dep-4. Methods, 2022, 204, 300-311.	1.9	3
12	Mental health before and during the pandemic in people with systemic sclerosis. Lancet Rheumatology, The, 2022, 4, e82-e85.	2.2	9
13	Experiences of Canadian mental health providers in identifying and responding to online and in-person sexual abuse and exploitation of their child and adolescent clients. Child Abuse and Neglect, 2022, 124, 105448.	1.3	11
14	Vascular risk factors and stroke risk across the life span: A population-representative study of half a million people. International Journal of Stroke, 2022, 17, 1021-1029.	2.9	2
15	Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry,the, 2022, 9, 137-150.	3.7	1,487
16	Productivity loss among people with early multiple sclerosis: A Canadian study. Multiple Sclerosis Journal, 2022, 28, 1414-1423.	1.4	12
17	Validity and reliability of global ratings of satisfaction with epilepsy surgery. Epilepsia, 2022, 63, 777-788.	2.6	3
18	Confidence, Training and Challenges for Canadian Child Advocacy Center Staff When Working with Cases of Online and In-person Child Sexual Exploitation. Journal of Child Sexual Abuse, 2022, 31, 297-315.	0.7	3

#	Article	IF	CITATIONS
19	Psychiatric Outcomes in ICU Patients With Family Visitation. Chest, 2022, 162, 578-587.	0.4	5
20	10-Year Trends in Healthcare Spending among Patients with Schizophrenia in Alberta, Canada. Canadian Journal of Psychiatry, 2022, , 070674372210828.	0.9	2
21	Measuring Stigma Towards People with Opioid Use Problems: Exploratory and Confirmatory Factor Analysis of the Opening Minds Provider Attitudes Towards Opioid-Use Scale (OM-PATOS). International Journal of Mental Health and Addiction, 2022, , 1-12.	4.4	1
22	Cannabinoids in the management of behavioral, psychological, and motor symptoms of neurocognitive disorders: a mixed studies systematic review. Journal of Cannabis Research, 2022, 4, 11.	1.5	6
23	Understanding the impact of COVID-19 isolation measures on individuals with mood disorders in mental health clinics. Journal of Affective Disorders Reports, 2022, 8, 100348.	0.9	1
24	Association between antiseizure medications and quality of life in epilepsy: A mediation analysis. Epilepsia, 2022, 63, 440-450.	2.6	17
25	Use of Benzodiazepines and Z-Drugs in Multiple Sclerosis. Frontiers in Neurology, 2022, 13, 874724.	1.1	4
26	Depressive symptom trajectories and polygenic risk scores in individuals with an immune-mediated inflammatory disease. General Hospital Psychiatry, 2022, 77, 21-28.	1.2	5
27	Protocol for READY2Exit: a patient-oriented, mixed methods study examining transition readiness in adolescents with co-occurring physical and mental health conditions. Journal of Transition Medicine, 2022, 4, .	0.1	4
28	Measuring the Influence of Curricular Content and Personal Stories on Substance Use Stigma. Journal of Nursing Education, 2022, 61, 264-267.	0.4	2
29	Alternative scoring of the Patient Health Questionnaire-9 in neurological populations: an approach based on a predictive algorithm deriving from individual item scores. General Hospital Psychiatry, 2022, 77, 37-39.	1.2	1
30	Effect of mood and anxiety disorders on health care utilization in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1411-1420.	1.4	6
31	Rationale and Methodology of the 2018 Canadian Armed Forces Members and Veterans Mental Health Follow-up Survey (CAFVMHS): A 16-year Follow-up Survey: Raison D'être Et Méthodologie De L'enquêt De Suivi Sur La Santé Mentale Des Membres Des Forces Armées Canadiennes Et Des Anciens Combattants. 2018 (ESSMFACM). Canadian Journal of Psychiatry. 2021. 66. 942-950.	te 0.9	12
32	Prevalence of Mental Ill-Health in a Cohort of First Responders Attending the Fort McMurray Fire. Canadian Journal of Psychiatry, 2021, 66, 719-725.	0.9	7
33	A Viewpoint: Validation of Self-Reported Anxiety Screening Scales in Perinatal Populations– Outstanding Issues in the Validation Research Agenda. Canadian Journal of Nursing Research, 2021, 53, 187-190.	0.6	O
34	Our Digital Moment: Innovations and Opportunities in Digital Mental Health Care. Canadian Journal of Psychiatry, 2021, 66, 5-8.	0.9	43
35	Assessment of anxiety during pregnancy: are existing multiple anxiety scales suitable and comparable in measuring anxiety during pregnancy?. Journal of Psychosomatic Obstetrics and Gynaecology, 2021, 42, 140-146.	1.1	8
36	Prevalence and Risk Factors of Substance Use Disorder in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2021, 27, 58-64.	0.9	12

#	Article	IF	Citations
37	Cannabis and non-psychotic mental disorders. Current Opinion in Psychology, 2021, 38, 61-66.	2.5	4
38	Impact of Psychiatric Comorbidity on Health Care Use in Rheumatoid Arthritis: A Populationâ€Based Study. Arthritis Care and Research, 2021, 73, 90-99.	1.5	6
39	<i>P</i> Values and Confidence Intervals. Canadian Journal of Psychiatry, 2021, 66, 421-422.	0.9	0
40	Depression prevalence based on the Edinburgh Postnatal Depression Scale compared to Structured Clinical Interview for DSM DIsorders classification: Systematic review and individual participant data metaâ€analysis. International Journal of Methods in Psychiatric Research, 2021, 30, e1860.	1.1	30
41	Emerging Patterns of E-Cigarette Use in the General Population. Canadian Journal of Psychiatry, 2021, 66, 503-505.	0.9	7
42	Risk of Depression in Patients With Psoriatic Disease: A Systematic Review and Meta-Analysis. Journal of Cutaneous Medicine and Surgery, 2021, 25, 257-270.	0.6	15
43	How a shared humanity model can improve provider well-being and client care: An evaluation of Fraser Health's Trauma and Resiliency Informed Practice (TRIP) training program. Healthcare Management Forum, 2021, 34, 87-92.	0.6	5
44	Factors associated with fears due to COVID-19: A Scleroderma Patient-centered Intervention Network (SPIN) COVID-19 cohort study. Journal of Psychosomatic Research, 2021, 140, 110314.	1.2	9
45	Primary care electronic medical records can be used to predict risk and identify potentially modifiable factors for early and late death in adult onset epilepsy. Epilepsia, 2021, 62, 51-60.	2.6	9
46	Probability of Major Depression Classification Based on the SCID, CIDI, and MINI Diagnostic Interviews: A Synthesis of Three Individual Participant Data Meta-Analyses. Psychotherapy and Psychosomatics, 2021, 90, 28-40.	4.0	20
47	The Relationship Between Symptoms of Depression and Anxiety and Disease Activity in IBD Over Time. Inflammatory Bowel Diseases, 2021, 27, 1285-1293.	0.9	64
48	Course and Predictors of Major Depressive Disorder in the Canadian Armed Forces Members and Veterans Mental Health Follow-up Survey: Cours et Prédicteurs du Trouble de Dépression Majeure Dans l'Enquête de Suivi Sur la Sant© Mentale AuprÓs Des Membres des Forces Armées Canadiennes et des ex-Militaires. Canadian Journal of Psychiatry, 2021, 66, 971-981.	0.9	10
49	Screening for depression in children and adolescents: a protocol for a systematic review update. Systematic Reviews, 2021, 10, 24.	2.5	11
50	Capacity, confidence and training of Canadian educators and school staff to recognize and respond to sexual abuse and internet exploitation of their students. Child Abuse and Neglect, 2021, 112, 104898.	1.3	11
51	Poor Mental Health during the COVD-19 Pandemic: Effect Modification by Age. Canadian Journal of Psychiatry, 2021, 66, 827-829.	0.9	14
52	Birth outcomes, pregnancy complications, and postpartum mental health after the 2013 Calgary flood: A difference in difference analysis. PLoS ONE, 2021, 16, e0246670.	1.1	20
53	Outdoor Air Pollution and Depression in Canada: A Population-Based Cross-Sectional Study from 2011 to 2016. International Journal of Environmental Research and Public Health, 2021, 18, 2450.	1.2	12
54	Patterns of Attrition in the Canadian Armed Forces Members and Veterans Mental Health Follow-up Survey (CAFVMHS). Canadian Journal of Psychiatry, 2021, 66, 996-998.	0.9	13

#	Article	IF	CITATIONS
55	Population Mental Health and COVID-19: Why Do We Know So Little?. Canadian Journal of Psychiatry, 2021, 66, 070674372110105.	0.9	7
56	Comparative Efficacy and Acceptability of Psychotherapies for Self-harm and Suicidal Behavior Among Children and Adolescents. JAMA Network Open, 2021, 4, e216614.	2.8	23
57	Uptake of influenza vaccination among persons with inflammatory bowel disease, multiple sclerosis or rheumatoid arthritis: a population-based matched cohort study. CMAJ Open, 2021, 9, E510-E521.	1.1	10
58	Childhood care and abuse in firefighters assessed for mental ill-health following the Fort McMurray fire of May 2016 Journal of Affective Disorders Reports, 2021, 4, 100090.	0.9	3
59	Accuracy of the Hospital Anxiety and Depression Scale Depression subscale (HADS-D) to screen for major depression: systematic review and individual participant data meta-analysis. BMJ, The, 2021, 373, n972.	3.0	77
60	The WHODAS-2 and Community Psychiatry. Canadian Journal of Psychiatry, 2021, 66, 1094-1095.	0.9	1
61	Impairment in health-related quality of life among community-dwelling stroke survivors. Canadian Journal of Neurological Sciences, 2021, , 1-23.	0.3	0
62	The association between childhood maltreatment and pain catastrophizing in individuals with immune-mediated inflammatory diseases. Journal of Psychosomatic Research, 2021, 145, 110479.	1.2	11
63	An environmental scan of visitation policies in Canadian intensive care units during the first wave of the COVID-19 pandemic. Canadian Journal of Anaesthesia, 2021, 68, 1474-1484.	0.7	31
64	The Burden of Mental Illness and Evidence-informed Mental Health Policy Development. Canadian Journal of Psychiatry, 2021, , 070674372110212.	0.9	2
65	Effects of a multi-faceted education and support programme on anxiety symptoms among people with systemic sclerosis and anxiety during COVID-19 (SPIN-CHAT): a two-arm parallel, partially nested, randomised, controlled trial. Lancet Rheumatology, The, 2021, 3, e427-e437.	2.2	24
66	The impact of providing personalized depression risk information on selfâ€help and helpâ€seeking behaviors: Results from a mixed methods randomized controlled trial. Depression and Anxiety, 2021, 38, 917-924.	2.0	3
67	Predicting postoperative epilepsy surgery satisfaction in adults using the 19â€item Epilepsy Surgery Satisfaction Questionnaire and machine learning. Epilepsia, 2021, 62, 2103-2112.	2.6	6
68	Quality of Life in Epilepsy: Same questions, but different meaning to different people. Epilepsia, 2021, 62, 2094-2102.	2.6	7
69	Mental Health Interventions to Improve Psychological Outcomes in Informal Caregivers of Critically Ill Patients: A Systematic Review and Meta-Analysis*. Critical Care Medicine, 2021, 49, 1414-1426.	0.4	15
70	Self-help behaviors partially mediate the relationship between personalized depression risk disclosure and psychological distress: A mediation analysis using data from a randomized controlled trial. Journal of Psychiatric Research, 2021, 140, 7-14.	1.5	0
71	Association Between Physical Activity and Mortality Among Community-Dwelling Stroke Survivors. Neurology, 2021, 97, .	1.5	6
72	Association Between Excess Leisure Sedentary Time and Risk of Stroke in Young Individuals. Stroke, 2021, 52, 3562-3568.	1.0	12

#	Article	IF	CITATIONS
73	Effect of comorbid mood and anxiety disorders on breast and cervical cancer screening in immune-mediated inflammatory disease. PLoS ONE, 2021, 16, e0249809.	1.1	6
74	The Prevalence of Cannabis Use Disorder Comorbidity in Individuals With Bipolar Disorder: A Systematic Review and Meta-Analysis. Canadian Journal of Addiction, 2021, 12, 22-38.	0.2	3
75	Impact of restricted visitation policies in hospitals on patients, family members and healthcare providers during the COVID-19 pandemic: a scoping review protocol. BMJ Open, 2021, 11, e048227.	0.8	6
76	Can the adverse childhood experiences (ACEs) checklist be utilized to predict emergency department visits among children and adolescents?. BMC Medical Research Methodology, 2021, 21, 195.	1.4	3
77	Self-Reported Lifetime History of Eating Disorders and Mortality in the General Population: A Canadian Population Survey with Record Linkage. Nutrients, 2021, 13, 3333.	1.7	4
78	Data-driven methods distort optimal cutoffs and accuracy estimates of depression screening tools: a simulation study using individual participant data. Journal of Clinical Epidemiology, 2021, 137, 137-147.	2.4	9
79	Prevalence and Risk Factors of Substance Use Disorder in Rheumatoid Arthritis. ACR Open Rheumatology, 2021, 3, 889-896.	0.9	3
80	Restricted visitation policies in acute care settings during the COVID-19 pandemic: a scoping review. Critical Care, 2021, 25, 347.	2.5	45
81	Healthcare utilization and mortality outcomes in patients with pre-existing psychiatric disorders after intensive care unit discharge: A population-based retrospective cohort study. Journal of Critical Care, 2021, 66, 67-74.	1.0	4
82	Shortening the Edinburgh postnatal depression scale using optimal test assembly methods: Development of the EPDSâ€Depâ€5. Acta Psychiatrica Scandinavica, 2021, 143, 348-362.	2.2	5
83	Understanding the impact of the COVID-19 pandemic on well-being and virtual care for people living with dementia and care partners living in the community. Dementia, 2021, 20, 2007-2023.	1.0	56
84	The Canadian prospective cohort study to understand progression in multiple sclerosis (CanProCo): rationale, aims, and study design. BMC Neurology, 2021, 21, 418.	0.8	5
85	26 Supporting the Transition to Postsecondary for Students with Mental Health Conditions: A Scoping Review. Paediatrics and Child Health, 2021, 26, e19-e21.	0.3	1
86	Global, regional, and national mortality among young people aged 10–24 years, 1950–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, The, 2021, 398, 1593-1618.	6.3	92
87	Vaping and Mental Health. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 2021, 30, 3-5.	0.7	5
88	Data Harmonization and Data Pooling from Cohort Studies: A Practical Approach for Data Management. International Journal of Population Data Science, 2021, 6, 1680.	0.1	14
89	Users' perceptions about receiving personalized depression risk information: findings from a qualitative study. BMC Psychiatry, 2021, 21, 581.	1.1	1
90	The Prevalence of Impulse Control Disorders and Behavioral Addictions in Eating Disorders: A Systematic Review and Meta-Analysis. Frontiers in Psychiatry, 2021, 12, 724034.	1.3	4

#	Article	IF	Citations
91	The effect of interventions targeting gut microbiota on depressive symptoms: a systematic review and meta-analysis. CMAJ Open, 2021, 9, E1195-E1204.	1.1	21
92	The prevalence of substance use disorders and substance use in anorexia nervosa: a systematic review and meta-analysis. Journal of Eating Disorders, 2021, 9, 161.	1.3	12
93	Recent Trends in the Prescribing of ADHD Medications in Canadian Primary Care. Journal of Attention Disorders, 2020, 24, 301-308.	1.5	9
94	Changing trends in coding for depression among the UK IBD population: reply from authors. Gut, 2020, 69, 607.2-607.	6.1	1
95	"lf it helps someone, then I want to do it― Perspectives of persons living with dementia on research registry participation. Dementia, 2020, 19, 2525-2541.	1.0	5
96	Validity and Reliability of Screening Measures for Depression and Anxiety Disorders in Rheumatoid Arthritis. Arthritis Care and Research, 2020, 72, 1130-1139.	1.5	63
97	Subtyping psychological distress in the population: a semi-parametric network approach. Epidemiology and Psychiatric Sciences, 2020, 29, e36.	1.8	1
98	Depression in inflammatory bowel disease: risk factor, prodrome or extraintestinal manifestation? Reply from authors. Gut, 2020, 69, 611-612.	6.1	2
99	Electronic cigarette use and mental health: A Canadian population-based study. Journal of Affective Disorders, 2020, 260, 646-652.	2.0	39
100	Seasonal variation in specific depressive symptoms: A population based study. Journal of Affective Disorders, 2020, 261, 153-159.	2.0	13
101	The Accuracy of the Patient Health Questionnaire-9 Algorithm for Screening to Detect Major Depression: An Individual Participant Data Meta-Analysis. Psychotherapy and Psychosomatics, 2020, 89, 25-37.	4.0	67
102	Equivalency of the diagnostic accuracy of the PHQ-8 and PHQ-9: a systematic review and individual participant data meta-analysis. Psychological Medicine, 2020, 50, 1368-1380.	2.7	175
103	Mental Health among Canadian Postsecondary Students: A Mental Health Crisis?. Canadian Journal of Psychiatry, 2020, 65, 30-35.	0.9	23
104	Does the neuropsychiatric inventory predict progression from mild cognitive impairment to dementia? A systematic review and meta-analysis. Ageing Research Reviews, 2020, 58, 101004.	5.0	17
105	On the need for epidemiology in psychiatric sciences. Epidemiology and Psychiatric Sciences, 2020, 29, e1.	1.8	9
106	Predicting death by suicide using administrative health care system data: Can recurrent neural network, one-dimensional convolutional neural network, and gradient boosted trees models improve prediction performance?. Journal of Affective Disorders, 2020, 264, 107-114.	2.0	16
107	Synthesis and biological assessment of a ruthenium(II) cyclopentadienyl complex in breast cancer cells and on the development of zebrafish embryos. European Journal of Medicinal Chemistry, 2020, 188, 112030.	2.6	31
108	Probability of major depression diagnostic classification based on the SCID, CIDI and MINI diagnostic interviews controlling for Hospital Anxiety and Depression Scale – Depression subscale scores: An individual participant data meta-analysis of 73 primary studies. Journal of Psychosomatic Research, 2020, 129, 109892.	1.2	33

#	Article	IF	CITATIONS
109	Social phobia in immune-mediated inflammatory diseases. Journal of Psychosomatic Research, 2020, 128, 109890.	1.2	6
110	Antidepressant Prescriptions, Including Tricyclics, Continue to Increase in Canadian Children. Journal of Child and Adolescent Psychopharmacology, 2020, 30, 381-388.	0.7	4
111	A Great Catch for Investigating Inborn Errors of Metabolism—Insights Obtained from Zebrafish. Biomolecules, 2020, 10, 1352.	1.8	8
112	Depression prevalence using the HADS-D compared to SCID major depression classification: An individual participant data meta-analysis. Journal of Psychosomatic Research, 2020, 139, 110256.	1.2	19
113	Mental disorders and subsequent suicide events in a representative community population. Journal of Affective Disorders, 2020, 277, 456-462.	2.0	6
114	Development and validation of the Epilepsy Surgery Satisfaction Questionnaire (ESSQâ€19). Epilepsia, 2020, 61, 2729-2738.	2.6	13
115	Validation of the COVID-19 Fears Questionnaires for Chronic Medical Conditions: A Scleroderma Patient-centered Intervention Network COVID-19 Cohort study. Journal of Psychosomatic Research, 2020, 139, 110271.	1.2	20
116	Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, The, 2020, 396, 1204-1222.	6.3	7,664
117	Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, The, 2020, 396, 1223-1249.	6.3	3,928
118	Five insights from the Global Burden of Disease Study 2019. Lancet, The, 2020, 396, 1135-1159.	6.3	335
119	16742 Depression as a risk factor for the development of psoriasis. Journal of the American Academy of Dermatology, 2020, 83, AB69.	0.6	1
120	Examining the impacts of the COVID-19 pandemic on the well-being and virtual care of patients with epilepsy. Epilepsy and Behavior, 2020, 113, 107599.	0.9	16
121	Accuracy of the Edinburgh Postnatal Depression Scale (EPDS) for screening to detect major depression among pregnant and postpartum women: systematic review and meta-analysis of individual participant data. BMJ, The, 2020, 371, m4022.	3.0	298
122	The Impact of Psychiatric Comorbidity on Health Care Utilization in Inflammatory Bowel Disease: A Population-based Study. Inflammatory Bowel Diseases, 2020, 27, 1462-1474.	0.9	10
123	Association between delirium in the intensive care unit and subsequent neuropsychiatric disorders. Critical Care, 2020, 24, 476.	2.5	15
124	Current perspectives on co-morbid depression and multiple sclerosis. Expert Review of Neurotherapeutics, 2020, 20, 867-874.	1.4	9
125	Modelling C9orf72-Related Amyotrophic Lateral Sclerosis in Zebrafish. Biomedicines, 2020, 8, 440.	1.4	10
126	Changes in mental health symptoms from pre-COVID-19 to COVID-19 among participants with systemic sclerosis from four countries: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort study. Journal of Psychosomatic Research, 2020, 139, 110262.	1.2	25

#	Article	IF	CITATIONS
127	Overestimation of Postpartum Depression Prevalence Based on a 5-item Version of the EPDS: Systematic Review and Individual Participant Data Meta-analysis. Canadian Journal of Psychiatry, 2020, 65, 835-844.	0.9	9
128	The association of recreational and non-recreational physical activity with mental health: A Canadian cross-sectional analysis Journal of Affective Disorders Reports, 2020, 1, 100021.	0.9	5
129	Driving Under the Influence of Cannabis in Canada, 2015 to 2018. Canadian Journal of Psychiatry, 2020, 65, 674-675.	0.9	0
130	Mental Health of Communities during the COVID-19 Pandemic. Canadian Journal of Psychiatry, 2020, 65, 681-687.	0.9	157
131	Neighbourhood socioeconomic status modifies the association between anxiety and depression during pregnancy and preterm birth: a Community-based Canadian cohort study. BMJ Open, 2020, 10, e031035.	0.8	14
132	The relationship between depression risk perception and self-help behaviours in high risk Canadians: a cross-sectional study. BMC Public Health, 2020, 20, 876.	1.2	4
133	Validity of the Patient Health Questionnaire-9 in neurologic populations. Neurology: Clinical Practice, 2020, 10, 190-198.	0.8	13
134	Accuracy of the PHQ-2 Alone and in Combination With the PHQ-9 for Screening to Detect Major Depression. JAMA - Journal of the American Medical Association, 2020, 323, 2290.	3.8	242
135	The Association of Active Living Environments and Mental Health: A Canadian Epidemiological Analysis. International Journal of Environmental Research and Public Health, 2020, 17, 1910.	1.2	7
136	Maternal chronic disease and breastfeeding outcomes: a Canadian population-based study. Journal of Maternal-Fetal and Neonatal Medicine, 2020, , $1\text{-}8$.	0.7	12
137	Predicting death by suicide following an emergency department visit for parasuicide with administrative health care system data and machine learning. EClinicalMedicine, 2020, 20, 100281.	3.2	25
138	Patient Health Questionnaire-9 scores do not accurately estimate depression prevalence: individual participant data meta-analysis. Journal of Clinical Epidemiology, 2020, 122, 115-128.e1.	2.4	113
139	The accuracy of depression risk perception in high risk Canadians. Journal of Affective Disorders, 2020, 265, 410-415.	2.0	7
140	Cannabis Use and Internalizing/Externalizing Symptoms in Youth: A Canadian Population-Based Study. Journal of Adolescent Health, 2020, 67, 26-32.	1.2	7
141	Incidence and temporal trends of co-occurring personality disorder diagnoses in immune-mediated inflammatory diseases. Epidemiology and Psychiatric Sciences, 2020, 29, e84.	1.8	4
142	Estimating the sample mean and standard deviation from commonly reported quantiles in meta-analysis. Statistical Methods in Medical Research, 2020, 29, 2520-2537.	0.7	366
143	Incidence of Adverse Psychiatric Events During Treatment of Inflammatory Bowel Disease With Biologic Therapies: A Systematic Review. Crohn's & Colitis 360, 2020, 2, otz053.	0.5	8
144	Depression as a risk factor for the development of psoriasis: a retrospective cohort study in the <scp>UK</scp> . British Journal of Dermatology, 2020, 183, 776-778.	1.4	7

#	Article	IF	CITATIONS
145	A growing need for youth mental health services in Canada: examining trends in youth mental health from 2011 to 2018. Epidemiology and Psychiatric Sciences, 2020, 29, e115.	1.8	108
146	Smoking Cessation and Improvement in Mental Health Outcomes: Do People Who Quit Smoking by Switching to Electronic Cigarettes Experience Improvement in Mental Health?. Canadian Journal of Psychiatry, 2020, 65, 512-514.	0.9	7
147	Protocol for a partially nested randomised controlled trial to evaluate the effectiveness of the scleroderma patient-centered intervention network COVID-19 home-isolation activities together (SPIN-CHAT) program to reduce anxiety among at-risk scleroderma patients. Journal of Psychosomatic Research, 2020, 135, 110132.	1.2	21
148	Psychosocial profiles and their predictors in epilepsy using patientâ€reported outcomes and machine learning. Epilepsia, 2020, 61, 1201-1210.	2.6	10
149	The Effects of microRNA-515-5p on the Toll-Like Receptor 4 (TLR4)/JNK Signaling Pathway and WNT1-Inducible-Signaling Pathway Protein 1 (WISP-1) Expression in Rheumatoid Arthritis Fibroblast-Like Synovial (RAFLS) Cells Following Treatment with Receptor Activator of Nuclear Factor-kappa-B Ligand (RANKL). Medical Science Monitor, 2020, 26, e920611.	0.5	8
150	Mandatory HIV screening, migration and HIV stigma in Canada: exploring the experiences of sub-Saharan African immigrants living with HIV in western Canada. Health Promotion and Chronic Disease Prevention in Canada: Research, Policy and Practice, 2020, 40, 38-46.	0.8	8
151	Sexualized drug use in virtual space: A scoping review of how gay, bisexual and other men who have sex with men interact online. Canadian Journal of Human Sexuality, 2020, 29, 106-126.	0.6	9
152	Mental Disorders and Subsequent Suicide in A Representative Community Population. International Journal of Population Data Science, 2020, 5, .	0.1	0
153	Physical Activity and Mental Health: A Cross-sectional Study of Canadian Youth. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 2020, 29, 241-252.	0.7	2
154	Child abuse and all-cause mortality in the Canadian population. European Journal of Public Health, 2020, 30, .	0.1	0
155	Increased Burden of Psychiatric Disorders in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2019, 25, 360-368.	0.9	166
156	Mental health care for university students: a way forward? Lancet Psychiatry, the, 2019, 6, 885-887.	3.7	111
157	Predicting death by suicide using administrative health care system data: Can feedforward neural network models improve upon logistic regression models?. Journal of Affective Disorders, 2019, 257, 741-747.	2.0	13
158	The Pharmacoepidemiology of Psychotropic Medication Use in Canadian Children from 2012 to 2016. Journal of Child and Adolescent Psychopharmacology, 2019, 29, 740-745.	0.7	17
159	Association of Levels of Specialized Care With Risk of Premature Mortality in Patients With Epilepsy. JAMA Neurology, 2019, 76, 1352.	4.5	40
160	Psychopharmacology of multiple sclerosis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2019, 165, 309-315.	1.0	3
161	Risk of adverse perinatal outcomes among women with pharmacologically treated and untreated depression during pregnancy: A retrospective cohort study. Paediatric and Perinatal Epidemiology, 2019, 33, 323-331.	0.8	13
162	Comparison of major depression diagnostic classification probability using the SCID, CIDI, and MINI diagnostic interviews among women in pregnancy or postpartum: An individual participant data metaâ€analysis. International Journal of Methods in Psychiatric Research, 2019, 28, e1803.	1.1	34

#	Article	IF	CITATIONS
163	A randomized controlled trial to examine the impacts of disclosing personalized depression risk information on the outcomes of individuals who are at high risk of developing major depression: a research protocol. BMC Psychiatry, 2019, 19, 285.	1.1	8
164	Validation of a case definition for depression in administrative data against primary chart data as a reference standard. BMC Psychiatry, 2019, 19, 9.	1.1	76
165	Prediction Tools for Psychiatric Adverse Effects After Levetiracetam Prescription. JAMA Neurology, 2019, 76, 440.	4.5	73
166	Screening for depression in women during pregnancy or the first year postpartum and in the general adult population: a protocol for two systematic reviews to update a guideline of the Canadian Task Force on Preventive Health Care. Systematic Reviews, 2019, 8, 27.	2.5	30
167	Resolving the paradox of increased mental health expenditure and stable prevalence. Australian and New Zealand Journal of Psychiatry, 2019, 53, 844-850.	1.3	21
168	Seasonal variation in symptoms of depression: A Canadian population based study. Journal of Affective Disorders, 2019, 255, 142-149.	2.0	29
169	Gender differences in information needs and preferences regarding depression among individuals with multiple sclerosis, inflammatory bowel disease and rheumatoid arthritis. Patient Education and Counseling, 2019, 102, 1722-1729.	1.0	12
170	The 2014 Ontario Child Health Study. Canadian Journal of Psychiatry, 2019, 64, 225-226.	0.9	1
171	The Prevalence and Risk Factors of Undiagnosed Depression and Anxiety Disorders Among Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2019, 25, 1674-1680.	0.9	73
172	Assessment of the burden of diseases and injuries attributable to risk factors in Canada from 1990 to 2016: an analysis of the Global Burden of Disease Study. CMAJ Open, 2019, 7, E140-E148.	1.1	29
173	Living with Migraine in Canada – A National Community-Based Study. Canadian Journal of Neurological Sciences, 2019, 46, 216-223.	0.3	6
174	Accuracy of Patient Health Questionnaire-9 (PHQ-9) for screening to detect major depression: individual participant data meta-analysis. BMJ: British Medical Journal, 2019, 365, 11476.	2.4	822
175	Global assessment of migraine severity measure: preliminary evidence of construct validity. BMC Neurology, 2019, 19, 53.	0.8	17
176	Does neighborhood socioeconomic status predict the risk of preterm birth? A community-based Canadian cohort study. BMJ Open, 2019, 9, e025341.	0.8	9
177	Global, regional, and national burden of suicide mortality 1990 to 2016: systematic analysis for the Global Burden of Disease Study 2016. BMJ: British Medical Journal, 2019, 364, 194.	2.4	558
178	Could Depression be Preventable? Evidence and Perspectives. , 2019, , 257-263.		0
179	Lithium, an Infrequently Used Medication. Canadian Journal of Psychiatry, 2019, 65, 070674371989071.	0.9	0
180	Depression and the risk of rheumatoid arthritis. Current Opinion in Rheumatology, 2019, 31, 279-284.	2.0	75

#	Article	IF	Citations
181	Burden of Mental, Neurological, Substance Use Disorders and Self-Harm: Counting the Cards, or Shuffling the Deck?. Canadian Journal of Psychiatry, 2019, 65, 070674371989270.	0.9	0
182	Major depressive episodes and mortality in the Canadian household population. Journal of Affective Disorders, 2019, 242, 165-171.	2.0	8
183	Increasing Rates of Arthroplasty for Psoriatic Arthritis in the United Kingdom Between 1995 and 2010. Arthritis Care and Research, 2019, 71, 1525-1529.	1.5	5
184	Assessment of a Bidirectional Association Between Major Depressive Disorder and Alopecia Areata. JAMA Dermatology, 2019, 155, 475.	2.0	40
185	Vitiligo and major depressive disorder: A bidirectional population-based cohort study. Journal of the American Academy of Dermatology, 2019, 80, 1371-1379.	0.6	34
186	Comorbid anxiety, depression, and cognition in MS and other immune-mediated disorders. Neurology, 2019, 92, .	1.5	79
187	Depression increases the risk of inflammatory bowel disease, which may be mitigated by the use of antidepressants in the treatment of depression. Gut, 2019, 68, 1606-1612.	6.1	155
188	Shortening self-report mental health symptom measures through optimal test assembly methods: Development and validation of the Patient Health Questionnaire-Depression-4. Depression and Anxiety, 2019, 36, 82-92.	2.0	16
189	Adherence to and Persistence with Antidepressant Medication during Pregnancy: Does It Differ by the Class of Antidepressant Medication Prescribed?. Canadian Journal of Psychiatry, 2019, 64, 199-208.	0.9	13
190	Rising incidence of psychiatric disorders before diagnosis of immune-mediated inflammatory disease. Epidemiology and Psychiatric Sciences, 2019, 28, 333-342.	1.8	91
191	Workplace Mental Health Training in Health Care: Key Ingredients of Implementation. Canadian Journal of Psychiatry, 2018, 63, 834-841.	0.9	27
192	Depressive Symptomatology, Syndromal Depression, and HIV-Associated Neurocognitive Disorder (HAND). Canadian Journal of Psychiatry, 2018, 63, 284-286.	0.9	0
193	Beyond Silence: A Randomized, Parallel-Group Trial Exploring the Impact of Workplace Mental Health Literacy Training with Healthcare Employees. Canadian Journal of Psychiatry, 2018, 63, 826-833.	0.9	57
194	Is depression screening in patients with acne critical?: reply from authors. British Journal of Dermatology, 2018, 179, 227-228.	1.4	0
195	Effects of depression and anxiety on quality of life in five common neurological disorders. General Hospital Psychiatry, 2018, 52, 58-63.	1.2	52
196	Barriers and Facilitators for Guidelines with Depression and Anxiety in Parkinson's Disease or Dementia. Canadian Journal on Aging, 2018, 37, 185-199.	0.6	10
197	Validating screening tools for depression in Parkinson's disease. Movement Disorders, 2018, 33, 1184-1186.	2.2	9
198	The Validity and Reliability of Screening Measures for Depression and Anxiety Disorders in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2018, 24, 1867-1875.	0.9	84

#	Article	IF	CITATIONS
199	No Obesity Paradox in Pediatric Patients With Dilated Cardiomyopathy. JACC: Heart Failure, 2018, 6, 222-230.	1.9	14
200	The prevalence of anxiety and associated factors in persons with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2018, 19, 35-39.	0.9	47
201	Risk of depression among patients with acne in the U.K.: a population-based cohort study. British Journal of Dermatology, 2018, 178, e194-e195.	1.4	43
202	Increased Burden of Psychiatric Disorders in Rheumatoid Arthritis. Arthritis Care and Research, 2018, 70, 970-978.	1.5	100
203	Physical comorbidities increase the risk of psychiatric comorbidity in immune-mediated inflammatory disease. General Hospital Psychiatry, 2018, 51, 71-78.	1.2	19
204	The validity and reliability of screening measures for depression and anxiety disorders in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2018, 20, 9-15.	0.9	113
205	Clinical Profile of Persons with Multiple Sclerosis Across the Continuum of Care. Canadian Journal of Neurological Sciences, 2018, 45, 188-198.	0.3	10
206	Effects of physical comorbidities on disability progression in multiple sclerosis. Neurology, 2018, 90, e419-e427.	1.5	67
207	Probability of major depression diagnostic classification using semi-structured versus fully structured diagnostic interviews. British Journal of Psychiatry, 2018, 212, 377-385.	1.7	53
208	Cardiac and inflammatory biomarkers in perinatally HIV-infected and HIV-exposed uninfected children. Aids, 2018, 32, 1267-1277.	1.0	14
209	Validation of the PHQ-9 for Suicidal Ideation in Persons with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2018, 24, 1641-1648.	0.9	21
210	Psychiatric comorbidity is associated with disability progression in multiple sclerosis. Neurology, 2018, 90, e1316-e1323.	1.5	136
211	Patterns of association of chronic medical conditions and major depression. Epidemiology and Psychiatric Sciences, 2018, 27, 42-50.	1.8	41
212	Burnout in dermatology residents: a Canadian perspective. British Journal of Dermatology, 2018, 178, 270-271.	1.4	18
213	Prevalence of psychological distress: How do Australia and Canada compare?. Australian and New Zealand Journal of Psychiatry, 2018, 52, 227-238.	1.3	26
214	Efficacy and adverse events of oral isotretinoin for acne: a systematic review. British Journal of Dermatology, 2018, 178, 76-85.	1.4	110
215	Examining the Application of the Opening Minds Survey in the Community Health Centre Setting. Canadian Journal of Psychiatry, 2018, 63, 30-36.	0.9	14
216	Patterns of change in anxiety and depression during pregnancy predict preterm birth. Journal of Affective Disorders, 2018, 227, 71-78.	2.0	24

#	Article	IF	Citations
217	Systemic retinoids and psychiatric disorders in patients with skin diseases: a multifactorial relationship. British Journal of Dermatology, 2018, 178, 305-305.	1.4	1
218	Major depression and secondhand smoke exposure. Journal of Affective Disorders, 2018, 225, 260-264.	2.0	34
219	Does age matter? Comparing postâ€treatment psychosocial outcomes in young adult and older adult cancer survivors with their cancerâ€free peers. Psycho-Oncology, 2018, 27, 1404-1411.	1.0	59
220	Maternal mortality and morbidity burden in the Eastern Mediterranean Region: findings from the Global Burden of Disease 2015 study. International Journal of Public Health, 2018, 63, 47-61.	1.0	9
221	The burden of mental disorders in the Eastern Mediterranean region, 1990–2015: findings from the global burden of disease 2015 study. International Journal of Public Health, 2018, 63, 25-37.	1.0	43
222	Diagnoses of Depression and Anxiety Versus Current Symptoms and Quality of Life in Multiple Sclerosis. International Journal of MS Care, 2018, 20, 76-84.	0.4	35
223	Cardiac status of perinatally HIV-infected children. Aids, 2018, 32, 2337-2346.	1.0	8
224	Global Burden of Disease Study trends for Canada from 1990 to 2016. Cmaj, 2018, 190, E1296-E1304.	0.9	43
225	Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1684-1735.	6.3	716
226	The "Clinician's illusion―and the epidemiology, diagnosis and treatment of depressive disorders. BMC Psychiatry, 2018, 18, 395.	1.1	4
227	Controlled trial of the impact of a BC adult mental health practice support program (AMHPSP) on primary health care professionals' management of depression. BMC Family Practice, 2018, 19, 183.	2.9	4
228	Patient satisfaction with epilepsy surgery: what is important to patients?. Epileptic Disorders, 2018, 20, 364-373.	0.7	13
229	Diagnostic accuracy of the Geriatric Depression Scale-30, Geriatric Depression Scale-15, Geriatric Depression Scale-5 and Geriatric Depression Scale-4 for detecting major depression: protocol for a systematic review and individual participant data meta-analysis. BMJ Open, 2018, 8, e026598.	0.8	24
230	Efficacy and tolerability of lithium for the treatment of acute mania in children with bipolar disorder: A systematic review. Bipolar Disorders, 2018, 20, 583-593.	1.1	17
231	Adverse psychiatric effects of disease-modifying therapies in multiple Sclerosis: A systematic review. Multiple Sclerosis and Related Disorders, 2018, 26, 124-156.	0.9	33
232	Comorbidities Are Associated with Altered Health Services Use in Multiple Sclerosis: A Prospective Cohort Study. Neuroepidemiology, 2018, 51, 1-10.	1,1	18
233	The antidepressant mirtazapine improves survival in patients with primary biliary cholangitis. Journal of Hepatology, 2018, 68, S214-S215.	1.8	0
234	The impact of depression and antidepressant usage on primary biliary cholangitis clinical outcomes. PLoS ONE, 2018, 13, e0194839.	1.1	22

#	Article	IF	Citations
235	Social support and maternal mental health at 4 months and 1 year postpartum: analysis from the All Our Families cohort. Journal of Epidemiology and Community Health, 2018, 72, 933-939.	2.0	48
236	Psychiatric comorbidity increases mortality in immune-mediated inflammatory diseases. General Hospital Psychiatry, 2018, 53, 65-72.	1.2	73
237	Factors associated with perceived need for mental health care in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2018, 25, 179-185.	0.9	14
238	The effect of child hunger on educational attainment and early childbearing outcomes in a longitudinal population sample of Canadian youth. Paediatrics and Child Health, 2018, 23, e77-e84.	0.3	2
239	Safety of psychotropic medicines: looking beyond randomised evidence. Epidemiology and Psychiatric Sciences, 2018, 27, 529-530.	1.8	1
240	Second-generation antipsychotics and metabolic side-effects: Canadian population-based study. BJPsych Open, 2018, 4, 256-261.	0.3	8
241	Depression as a risk factor for the development of rheumatoid arthritis: a population-based cohort study. RMD Open, 2018, 4, e000670.	1.8	48
242	Prescription trends and psychiatric symptoms following first receipt of one of seven common antiepileptic drugs in general practice. Epilepsy and Behavior, 2018, 84, 49-55.	0.9	10
243	Psoriasis and the risk of foot and ankle tendinopathy or enthesopathy in the absence of psoriatic arthritis: a population-based study. RMD Open, 2018, 4, e000668.	1.8	3
244	Effects of Psychiatric Comorbidity in Immune-Mediated Inflammatory Disease: Protocol for a Prospective Study. JMIR Research Protocols, 2018, 7, e15.	0.5	38
245	Canadian trends in opioid-related mortality and disability from opioid use disorder from 1990 to 2014 through the lens of the Global Burden of Disease Study. Health Promotion and Chronic Disease Prevention in Canada: Research, Policy and Practice, 2018, 38, 234-243.	0.8	43
246	Seasonal variation in major depressive episode prevalence in Canada. Epidemiology and Psychiatric Sciences, 2017, 26, 169-176.	1.8	34
247	Descriptive Epidemiology of Generalized Anxiety Disorder in Canada. Canadian Journal of Psychiatry, 2017, 62, 24-29.	0.9	40
248	Depression screening tools in persons with epilepsy: A systematic review of validated tools. Epilepsia, 2017, 58, 695-705.	2.6	106
249	Increased incidence and prevalence of psoriasis in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2017, 13, 81-86.	0.9	28
250	Association of Depression and Treated Depression With Epilepsy and Seizure Outcomes. JAMA Neurology, 2017, 74, 533.	4.5	139
251	Depression Is Associated with an Increased Risk of Psoriatic Arthritis among Patients with Psoriasis: A Population-Based Study. Journal of Investigative Dermatology, 2017, 137, 828-835.	0.3	70
252	Impact of Skill-Based Approaches in Reducing Stigma in Primary Care Physicians: Results from a Double-Blind, Parallel-Cluster, Randomized Controlled Trial. Canadian Journal of Psychiatry, 2017, 62, 327-335.	0.9	34

#	Article	IF	Citations
253	Has increased provision of treatment reduced the prevalence of common mental disorders? Review of the evidence from four countries. World Psychiatry, 2017, 16, 90-99.	4.8	352
254	Differences in Presentation and Outcomes Between Children With Familial Dilated Cardiomyopathy and Children With Idiopathic Dilated Cardiomyopathy. Circulation: Heart Failure, 2017, 10, .	1.6	30
255	Mind the gap: Exploring information gaps for the development of an online resource hub for epilepsy and depression. Epilepsy and Behavior, 2017, 70, 18-23.	0.9	9
256	Selective Cutoff Reporting in Studies of Diagnostic Test Accuracy: A Comparison of Conventional and Individual-Patient-Data Meta-Analyses of the Patient Health Questionnaire-9 Depression Screening Tool. American Journal of Epidemiology, 2017, 185, 954-964.	1.6	45
257	Prevalence of Depression in Patients With Mild Cognitive Impairment. JAMA Psychiatry, 2017, 74, 58.	6.0	342
258	Determinants and incidence of depression in multiple sclerosis: A prospective cohort study. Journal of Psychosomatic Research, 2017, 99, 169-176.	1.2	28
259	Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015. Lancet, The, 2017, 390, 231-266.	6.3	480
260	Major depression and non-specific distress following smoking cessation in the Canadian general population. Journal of Affective Disorders, 2017, 218, 182-187.	2.0	13
261	Prevalence of Psychiatric Disorders is Increased Five Years before the Diagnosis in IBD. Gastroenterology, 2017, 152, S973.	0.6	3
262	Evaluating Mental Health Literacy in the Workplace: Development and Psychometric Properties of a Vignette-Based Tool. Journal of Occupational Rehabilitation, 2017, 27, 601-611.	1.2	20
263	Efficacy and tolerability of lithium in treating acute mania in youth with bipolar disorder: protocol for a systematic review. International Journal of Bipolar Disorders, 2017, 5, 22.	0.8	5
264	The prevalence of depression and the accuracy of depression screening tools in migraine patients. General Hospital Psychiatry, 2017, 48, 25-31.	1.2	21
265	Second-Generation Antipsychotics and Metabolic Side Effects: A Systematic Review of Population-Based Studies. Drug Safety, 2017, 40, 771-781.	1.4	136
266	Systematic Review and Meta-analysis of Interventions for Depression and Anxiety in Persons With Rheumatoid Arthritis. Journal of Clinical Rheumatology, 2017, 23, 425-434.	0.5	75
267	The prevalence of anxiety and associated factors in persons with epilepsy. Epilepsia, 2017, 58, e107-e110.	2.6	59
268	Trends in antidepressant prescribing to children and adolescents in ⟨scp⟩Canadian⟨ scp⟩ primary care: ⟨scp⟩A⟨ scp⟩ timeâ€series analysis. Pharmacoepidemiology and Drug Safety, 2017, 26, 1093-1099.	0.9	17
269	Age of Onset of Mental Disorders. Canadian Journal of Psychiatry, 2017, 62, 235-236.	0.9	19
270	Depression in epilepsy, migraine, and multiple sclerosis. Neurology: Clinical Practice, 2017, 7, 118-127.	0.8	13

#	Article	IF	CITATIONS
271	The impact of seizures on epilepsy outcomes: A national, communityâ€based survey. Epilepsia, 2017, 58, 764-771.	2.6	53
272	The pervasive effect of youth self-report of hunger on depression over 6Âyears of follow up. Social Psychiatry and Psychiatric Epidemiology, 2017, 52, 537-547.	1.6	23
273	Is the prevalence of major depression increasing in the Canadian adolescent population? Assessing trends from 2000 to 2014. Journal of Affective Disorders, 2017, 210, 22-26.	2.0	35
274	The association of antidepressant drug usage with cognitive impairment or dementia, including Alzheimer disease: A systematic review and meta-analysis. Depression and Anxiety, 2017, 34, 217-226.	2.0	80
275	Prevalence and incidence of epilepsy. Neurology, 2017, 88, 296-303.	1.5	1,141
276	Serotonin reuptake inhibitors and mortality in epilepsy: A linked primaryâ€care cohort study. Epilepsia, 2017, 58, 2002-2009.	2.6	8
277	Cardiac Effects of Highly Active Antiretroviral Therapy in Perinatally HIV-Infected Children. Journal of the American College of Cardiology, 2017, 70, 2240-2247.	1.2	24
278	Feasibility and Relevance of Antipsychotic Safety Monitoring in Children With Tourette Syndrome. Journal of Clinical Psychopharmacology, 2017, 37, 498-504.	0.7	21
279	Does Lowering Heart Rate Improve Outcomes in Children With DilatedÂCardiomyopathy and ChronicÂHeart Failure?. Journal of the American College of Cardiology, 2017, 70, 1273-1275.	1.2	4
280	Depression Screening and Health Outcomes in Children and Adolescents: A Systematic Review. Canadian Journal of Psychiatry, 2017, 62, 813-817.	0.9	18
281	Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1084-1150.	6.3	573
282	Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1260-1344.	6.3	1,589
283	Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1151-1210.	6.3	3,565
284	Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1211-1259.	6.3	5,578
285	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1345-1422.	6.3	1,879
286	Mental health and chronic diseases: a challenge to be faced from a new perspective. International Review of Psychiatry, 2017, 29, 373-376.	1.4	14
287	Under-diagnosis of mood disorders in Canada. Epidemiology and Psychiatric Sciences, 2017, 26, 414-423.	1.8	19
288	The depression and marital status relationship is modified by both age and gender. Journal of Affective Disorders, 2017, 223, 65-68.	2.0	114

#	Article	IF	Citations
289	Disaster Management and Farm Family Mental Health: The BSE Crisis as a Case Study. Prehospital and Disaster Medicine, 2017, 32, S185-S186.	0.7	O
290	Increased incidence of psychiatric disorders in immune-mediated inflammatory disease. Journal of Psychosomatic Research, 2017, 101, 17-23.	1.2	131
291	Analysis of myocardial fibrosis in children with hypertrophic cardiomyopathy: A report from the pediatric cardiomyopathy registry. Progress in Pediatric Cardiology, 2017, 46, 33.	0.2	0
292	Author response: Prevalence and incidence of epilepsy: A systematic review and meta-analysis of international studies. Neurology, 2017, 89, 641-642.	1.5	5
293	Disease-Modifying Therapies and Adherence in Multiple Sclerosis: Comparing Patient Self-Report with Pharmacy Records. Neuroepidemiology, 2017, 48, 124-130.	1.1	6
294	Online tools for individuals with depression and neurologic conditions. Neurology: Clinical Practice, 2017, 7, 344-353.	0.8	4
295	Survival Without Cardiac Transplantation Among Children With DilatedÂCardiomyopathy. Journal of the American College of Cardiology, 2017, 70, 2663-2673.	1.2	59
296	Comorbidity increases the risk of relapse in multiple sclerosis. Neurology, 2017, 89, 2455-2461.	1.5	77
297	Depression in multiple sclerosis. International Review of Psychiatry, 2017, 29, 463-472.	1.4	146
298	Homelessness and Mental Health. Canadian Journal of Psychiatry, 2017, 62, 440-441.	0.9	7
299	A comparison of recommendations and received treatment for mood and anxiety disorders in a representative national sample. BMC Psychiatry, 2017, 17, 155.	1.1	1
300	The Prevalence of Major Depressive Episodes Is Higher in Urban Regions of Canada. Canadian Journal of Psychiatry, 2017, 62, 57-61.	0.9	15
301	Major Depression Prevalence Increases with Latitude in Canada. Canadian Journal of Psychiatry, 2017, 62, 62-66.	0.9	12
302	Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross-Canada prospective study. Multiple Sclerosis Journal, 2017, 23, 588-596.	1.4	44
303	Estimating annual prevalence of depression and anxiety disorder in multiple sclerosis using administrative data. BMC Research Notes, 2017, 10, 619.	0.6	38
304	Hospital treatment costs and length of stay associated with hypertension and multimorbidity after hemorrhagic stroke. BMC Neurology, 2017, 17, 158.	0.8	31
305	Discriminative ability of quality of life measures in multiple sclerosis. Health and Quality of Life Outcomes, 2017, 15, 246.	1.0	11
306	A T-type channel-calmodulin complex triggers αCaMKII activation. Molecular Brain, 2017, 10, 37.	1.3	22

#	Article	IF	CITATIONS
307	Minimal sufficient balance randomization for sequential randomized controlled trial designs: results from the ESCAPE trial. Trials, 2017, 18, 516.	0.7	8
308	Featured Canadian Research on Child, Adolescent, and Young Adult Psychiatry. Canadian Journal of Psychiatry, 2017, 62, 810-812.	0.9	0
309	Mobile-based blended learning for capacity building of health providers in rural Afghanistan. MHealth, 2017, 3, 14-14.	0.9	7
310	A comparison of bivariate, multivariate randomâ€effects, and Poisson correlated gammaâ€frailty models to metaâ€analyze individual patient data of ordinal scale diagnostic tests. Biometrical Journal, 2017, 59, 1317-1338.	0.6	4
311	Fighting Stigma in Canada: Opening Minds Anti-Stigma Initiative. , 2017, , 237-261.		5
312	Using OSCEs with simulation to maximise student learning and assess competencies in psychology: A pilot study. Focus on Health Professional Education, 2017, 18, 61.	0.3	6
313	Protocol: a cluster randomised control trial study exploring stigmatisation and recovery-based perspectives regarding mental illness and substance use problems among primary healthcare providers across Toronto, Ontario. BMJ Open, 2017, 7, e017044.	0.8	9
314	Self-management of mood and/or anxiety disorders through physical activity/exercise. Health Promotion and Chronic Disease Prevention in Canada: Research, Policy and Practice, 2017, 37, 149-159.	0.8	31
315	Re:. Nutricion Hospitalaria, 2017, 34, 1006-1008.	0.2	2
316	Trends in binge drinking in Canada from 1996 to 2013: a repeated cross-sectional analysis. CMAJ Open, 2016, 4, E599-E604.	1.1	12
317	Implementing a data sharing culture. Epidemiology and Psychiatric Sciences, 2016, 25, 289-290.	1.8	15
318	Systematic review of interventions for depression and anxiety in persons with inflammatory bowel disease. BMC Research Notes, 2016, 9, 404.	0.6	40
319	The Association of Smoking and Surgery in Inflammatory Bowel Disease is Modified by Age at Diagnosis. Clinical and Translational Gastroenterology, 2016, 7, e165.	1.3	15
320	Towards a clinically informed, dataâ€driven definition of elderly onset epilepsy. Epilepsia, 2016, 57, 298-305.	2.6	26
321	Predictors of long-term care placement in persons with dementia: a systematic review and meta-analysis. International Journal of Geriatric Psychiatry, 2016, 31, 1151-1171.	1.3	111
322	EDUCATIONAL ATTAINMENT AS A PROTECTIVE FACTOR FOR PSYCHIATRIC DISORDERS: FINDINGS FROM A NATIONALLY REPRESENTATIVE LONGITUDINAL STUDY. Depression and Anxiety, 2016, 33, 1013-1022.	2.0	48
323	Childhood adversity and subsequent mental health status in adulthood: screening for associations using two linked surveys. Epidemiology and Psychiatric Sciences, 2016, 25, 160-170.	1.8	15
324	Determinants of rebound burst responses in rat cerebellar nuclear neurons to physiological stimuli. Journal of Physiology, 2016, 594, 985-1003.	1.3	23

#	Article	IF	CITATIONS
325	Diagnostic accuracy of the Depression subscale of the Hospital Anxiety and Depression Scale (HADS-D) for detecting major depression: protocol for a systematic review and individual patient data meta-analyses. BMJ Open, 2016, 6, e011913.	0.8	22
326	Declining Incidence of Systolic Left Ventricular Dysfunction in Human Immunodeficiency Virus–Infected Individuals Treated With Highly Active Antiretroviral Therapy. American Journal of Cardiology, 2016, 117, 1194-1195.	0.7	12
327	Consistency in adult reporting of adverse childhood experiences. Psychological Medicine, 2016, 46, 543-549.	2.7	198
328	Frailty Trajectories After Treatment for Coronary Artery Disease in Older Patients. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 230-238.	0.9	20
329	Chronic lung disease and multiple sclerosis: Incidence, prevalence, and temporal trends. Multiple Sclerosis and Related Disorders, 2016, 8, 86-92.	0.9	14
330	Perceived Stigma among Recipients of Mental Health Care in the General Canadian Population. Canadian Journal of Psychiatry, 2016, 61, 480-488.	0.9	55
331	Differing trends in the incidence of vascular comorbidity in MS and the general population. Neurology: Clinical Practice, 2016, 6, 120-128.	0.8	42
332	The association between major depression prevalence and sex becomes weaker with age. Social Psychiatry and Psychiatric Epidemiology, 2016, 51, 203-210.	1.6	25
333	Characterization of Disability in Canadians with Mental Disorders Using an Abbreviated Version of a <i>DSM-5</i> Emerging Measure: The 12-Item WHO Disability Assessment Schedule (WHODAS) 2.0. Canadian Journal of Psychiatry, 2016, 61, 227-235.	0.9	37
334	Scaling-up of treatment of depression and anxiety. Lancet Psychiatry, the, 2016, 3, 603.	3.7	6
335	Physical comorbidities increase the risk of psychiatric comorbidity in multiple sclerosis. Brain and Behavior, 2016, 6, e00493.	1.0	24
336	Global, regional, and national levels of maternal mortality, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1775-1812.	6.3	740
337	Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1603-1658.	6.3	1,612
338	Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1459-1544.	6.3	4,934
339	Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1545-1602.	6.3	5,298
340	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1659-1724.	6.3	4,203
341	Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1725-1774.	6. 3	571
342	Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1813-1850.	6.3	413

#	Article	IF	Citations
343	Comparison of the estimated prevalence of mood and/or anxiety disorders in Canada between self-report and administrative data. Epidemiology and Psychiatric Sciences, 2016, 25, 360-369.	1.8	45
344	Updated CANMAT Guidelines for Treatment of Major Depressive Disorder. Canadian Journal of Psychiatry, 2016, 61, 504-505.	0.9	18
345	Guidelines for dementia or Parkinson's disease with depression or anxiety: a systematic review. BMC Neurology, 2016, 16, 244.	0.8	43
346	A grounded theory model for reducing stigma in health professionals in Canada. Acta Psychiatrica Scandinavica, 2016, 134, 53-62.	2.2	86
347	Suicidal ideation in persons with neurological conditions: prevalence, associations and validation of the PHQ-9 for suicidal ideation. General Hospital Psychiatry, 2016, 42, 22-26.	1.2	39
348	Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2015: the Global Burden of Disease Study 2015. Lancet HIV,the, 2016, 3, e361-e387.	2.1	461
349	Depressive symptoms and functional decline following coronary interventions in older patients with coronary artery disease: a prospective cohort study. BMC Psychiatry, 2016, 16, 277.	1.1	6
350	Mental Health in the Canadian Armed Forces. Canadian Journal of Psychiatry, 2016, 61, 4S-6S.	0.9	5
351	Progress in Pediatric Cardiology. Progress in Pediatric Cardiology, 2016, 40, 1.	0.2	0
352	Mental disorders and distress: Associations with demographics, remoteness and socioeconomic deprivation of area of residence across Australia. Australian and New Zealand Journal of Psychiatry, 2016, 50, 1169-1179.	1.3	45
353	Accuracy of Depression Screening Tools to Detect Major Depression in Children and Adolescents: A Systematic Review. Canadian Journal of Psychiatry, 2016, 61, 746-757.	0.9	34
354	Validating screening tools for depression in stroke and transient ischemic attack patients. International Journal of Psychiatry in Medicine, 2016, 51, 262-277.	0.8	50
355	Major Depression in Canada: What Has Changed over the Past 10 Years?. Canadian Journal of Psychiatry, 2016, 61, 80-85.	0.9	39
356	Differing trends in the incidence of vascular comorbidity in MS and the general population. Neurology: Clinical Practice, 2016, 6, 201-202.	0.8	0
357	Global and National Burden of Diseases and Injuries Among Children and Adolescents Between 1990 and 2013. JAMA Pediatrics, 2016, 170, 267.	3.3	479
358	An investigation into the psychosocial effects of the postictal state. Neurology, 2016, 86, 723-730.	1.5	15
359	Future research directions in pediatric cardiomyopathy. Progress in Pediatric Cardiology, 2016, 40, 35-39.	0.2	1
360	Why is major depression prevalence not changing?. Journal of Affective Disorders, 2016, 190, 93-97.	2.0	34

#	Article	IF	CITATIONS
361	Preventing pediatric cardiomyopathy: a 2015 outlook. Expert Review of Cardiovascular Therapy, 2016, 14, 321-339.	0.6	4
362	Overeating at dinner time among Japanese workers: Is overeating related to stress response and late dinner times?. Appetite, 2016, 101, 8-14.	1.8	12
363	Screening for Depression and Anxiety in Epilepsy. Neurologic Clinics, 2016, 34, 351-361.	0.8	48
364	Long-Term Effects of <i>In Utero</i> Antiretroviral Exposure: Systolic and Diastolic Function in HIV-Exposed Uninfected Youth. AIDS Research and Human Retroviruses, 2016, 32, 621-627.	0.5	17
365	Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis. Neurology, 2016, 86, 1287-1295.	1.5	79
366	Assessing the role of IKCa channels in generating the sAHP of CA1 hippocampal pyramidal cells. Channels, 2016, 10, 313-319.	1.5	22
367	Health-related quality of life in multiple sclerosis. Neurology, 2016, 86, 1417-1424.	1.5	156
368	Sex differences in comorbidity at diagnosis of multiple sclerosis. Neurology, 2016, 86, 1279-1286.	1.5	86
369	Health-Related Quality of Life and Functional Status Are Associated with Cardiac Status and Clinical Outcome in Children with Cardiomyopathy. Journal of Pediatrics, 2016, 170, 173-180.e4.	0.9	15
370	Transforming Healthcare Delivery: Integrating Dynamic Simulation Modelling and Big Data in Health Economics and Outcomes Research. Pharmacoeconomics, 2016, 34, 115-126.	1.7	35
371	Systematic review and meta-analysis of interventions for depression and anxiety in persons with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2016, 5, 12-26.	0.9	133
372	Adverse health behaviours are associated with depression and anxiety in multiple sclerosis: A prospective multisite study. Multiple Sclerosis Journal, 2016, 22, 685-693.	1.4	27
373	Preferred Features of E-Mental Health Programs for Prevention of Major Depression in Male Workers: Results From a Canadian National Survey. Journal of Medical Internet Research, 2016, 18, e132.	2.1	28
374	The Effects of an E-Mental Health Program and Job Coaching on the Risk of Major Depression and Productivity in Canadian Male Workers: Protocol for a Randomized Controlled Trial. JMIR Research Protocols, 2016, 5, e218.	0.5	11
375	Fatigue and Comorbidities in Multiple Sclerosis. International Journal of MS Care, 2016, 18, 96-104.	0.4	38
376	Screening Tools for Anxiety in People with Multiple Sclerosis. International Journal of MS Care, 2016, 18, 273-281.	0.4	24
377	Major depressive disorder: reification and (maybe) rheostasis. Epidemiology and Psychiatric Sciences, 2015, 24, 473-475.	1.8	3
378	The Prevalence of Major Depression is Not Changing. Canadian Journal of Psychiatry, 2015, 60, 31-34.	0.9	40

#	Article	IF	Citations
379	A Canadian Primary Care Sentinel Surveillance Network Study Evaluating Antidepressant Prescribing in Canada from 2006 to 2012. Canadian Journal of Psychiatry, 2015, 60, 564-570.	0.9	20
380	Prevalence of Bipolar I and II Disorder in Canada. Canadian Journal of Psychiatry, 2015, 60, 151-156.	0.9	31
381	Problems from the Past and Prevention for the Future. Canadian Journal of Psychiatry, 2015, 60, 4-5.	0.9	3
382	Psychiatric Epidemiology: It is about Much More Than Prevalence. Canadian Journal of Psychiatry, 2015, 60, 529-530.	0.9	1
383	Validity of four screening scales for major depression in MS. Multiple Sclerosis Journal, 2015, 21, 1064-1071.	1.4	77
384	A Valuable (and Ongoing) Study, the National Trajectory Project Addresses Many Myths about the Verdict of Not Criminally Responsible on Account of Mental Disorder. Canadian Journal of Psychiatry, 2015, 60, 93-95.	0.9	1
385	Healthâ€related behaviors and comorbidities in people with epilepsy: Changes in the past decade. Epilepsia, 2015, 56, 1973-1981.	2.6	17
386	Descriptive Epidemiology of Major Depressive Disorder in Canada in 2012. Canadian Journal of Psychiatry, 2015, 60, 23-30.	0.9	139
387	Correlates of disability related to seizures in persons with epilepsy. Epilepsia, 2015, 56, 1463-1469.	2.6	41
388	The Canadian Journal of Psychiatry in 2014 and beyond. Canadian Journal of Psychiatry, 2015, 60, 1-3.	0.9	10
389	Physical Activity Interventions in Schools for Improving Lifestyle in European Countries. Clinical Practice and Epidemiology in Mental Health, 2015, 11, 77-101.	0.6	49
390	Predictors of Well-Being in Resident Physicians: A Descriptive and Psychometric Study. Journal of Graduate Medical Education, 2015, 7, 70-74.	0.6	75
391	Medical models and metaphors for depression. Epidemiology and Psychiatric Sciences, 2015, 24, 303-308.	1.8	21
392	Functional variants of POC5 identified in patients with idiopathic scoliosis. Journal of Clinical Investigation, 2015, 125, 1124-1128.	3.9	87
393	Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2015, 386, 743-800.	6.3	4,951
394	Stigma towards borderline personality disorder: effectiveness and generalizability of an anti-stigma program for healthcare providers using a pre-post randomized design. Borderline Personality Disorder and Emotion Dysregulation, 2015, 2, 9.	1.1	50
395	IKCa Channels Are a Critical Determinant of the Slow AHP in CA1 Pyramidal Neurons. Cell Reports, 2015, 11, 175-182.	2.9	64
396	The Global Burden of Cancer 2013. JAMA Oncology, 2015, 1, 505.	3.4	2,269

#	Article	IF	Citations
397	PSYCHOSOCIAL STRESS PARTIALLY MEDIATES THE ASSOCIATION BETWEEN RACE AND PRENATAL DEPRESSIVE SYMPTOMS IN A SAMPLE OF PREGNANT WOMEN IN ALBERTA. Journal of Epidemiology and Community Health, 2015, 69, A4.2-A4.	2.0	0
398	Determinants of disease severity in adults with epilepsy: Results from the Neurological Diseases and Depression Study. Epilepsy and Behavior, 2015, 51, 170-175.	0.9	24
399	Diagnostic accuracy of the Edinburgh Postnatal Depression Scale (EPDS) for detecting major depression in pregnant and postnatal women: protocol for a systematic review and individual patient data meta-analyses. BMJ Open, 2015, 5, e009742.	0.8	46
400	Syndemic Vulnerability, Sexual and Injection Risk Behaviors, and HIV Continuum of Care Outcomes in HIV-Positive Injection Drug Users. AIDS and Behavior, 2015, 19, 684-693.	1.4	56
401	Depression in multiple sclerosis: A long-term longitudinal study. Multiple Sclerosis Journal, 2015, 21, 76-82.	1.4	66
402	Retrospective and prospectively assessed childhood adversity in association with major depression, alcohol consumption and painful conditions. Epidemiology and Psychiatric Sciences, 2015, 24, 158-165.	1.8	67
403	Associations of medical comorbidity, psychosis, pain, and capacity with psychiatric hospital length of stay in geriatric inpatients with and without dementia. International Psychogeriatrics, 2015, 27, 313-321.	0.6	14
404	Elevated Hospitalization Risk of Assisted Living Residents With Dementia in Alberta, Canada. Journal of the American Medical Directors Association, 2015, 16, 568-577.	1.2	34
405	Bupropion confirmed not to cause weight gain in a real-world clinical population. Evidence-Based Mental Health, 2015, 18, 57-57.	2.2	1
406	Cardiomyopathy Phenotypes and Outcomes for Children With Left Ventricular Myocardial Noncompaction: Results From the Pediatric Cardiomyopathy Registry. Journal of Cardiac Failure, 2015, 21, 877-884.	0.7	140
407	Identifying reprioritization response shift in a stroke caregiver population: a comparison of missing data methods. Quality of Life Research, 2015, 24, 529-540.	1.5	12
408	Adjunctive treatment with quetiapine for major depressive disorder: are the benefits of treatment worth the risks? BMJ, The, 2015, 350, h569-h569.	3.0	9
409	Substance-related and behavioural addiction problems: Two surveys of Canadian adults. Addiction Research and Theory, 2015, 23, 34-42.	1.2	20
410	Comorbidity is associated with pain-related activity limitations in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2015, 4, 470-476.	0.9	40
411	Differences in the burden of psychiatric comorbidity in MS vs the general population. Neurology, 2015, 85, 1972-1979.	1.5	106
412	Prevalence, predictors, and outcomes of cardiorenal syndrome in children with dilated cardiomyopathy: a report from the Pediatric Cardiomyopathy Registry. Pediatric Nephrology, 2015, 30, 2177-2188.	0.9	15
413	Seeing is believing: Biological information may reduce mental health stigma amongst physicians. Australian and New Zealand Journal of Psychiatry, 2015, 49, 751-752.	1.3	12
414	Mental illness stigma as a quality-of-care problem. Lancet Psychiatry, the, 2015, 2, 863-864.	3.7	49

#	Article	IF	CITATIONS
415	Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition. Lancet, The, 2015, 386, 2145-2191.	6.3	1,544
416	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2015, 386, 2287-2323.	6.3	2,184
417	Depression â€" a common disorder across a broad spectrum of neurological conditions: a cross-sectional nationally representative survey. General Hospital Psychiatry, 2015, 37, 507-512.	1.2	27
418	Beyond silence: protocol for a randomized parallel-group trial comparing two approaches to workplace mental health education for healthcare employees. BMC Medical Education, 2015, 15, 78.	1.0	29
419	Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2015, 385, 117-171.	6.3	5,847
420	Social judgments of behavioral versus substance-related addictions: A population-based study. Addictive Behaviors, 2015, 42, 24-31.	1.7	45
421	Long-Term Persistence with Injectable Therapy in Relapsing-Remitting Multiple Sclerosis: An 18-Year Observational Cohort Study. PLoS ONE, 2015, 10, e0123824.	1.1	25
422	The Wisdom of Crowds (Vox Populi) and Antidepressant Use. Clinical Practice and Epidemiology in Mental Health, 2015, 11, 1-3.	0.6	2
423	The Wisdom of Crowds (Vox Populi) and Antidepressant Use. Clinical Practice and Epidemiology in Mental Health, 2015, 11, 1-3.	0.6	2
424	Exploration of Undertreatment and Patterns of Treatment of Depression in Multiple Sclerosis. International Journal of MS Care, 2015, 17, 292-300.	0.4	36
425	Factors Associated with Early Deterioration after Spontaneous Intracerebral Hemorrhage: A Systematic Review and Meta-Analysis. PLoS ONE, 2014, 9, e96743.	1.1	65
426	The Role of Systematic Reviews and Meta-Analyses of Incidence and Prevalence Studies in Neuroepidemiology. Neuroepidemiology, 2014, 42, 16-24.	1.1	21
427	The diagnostic accuracy of the Patient Health Questionnaire-2 (PHQ-2), Patient Health Questionnaire-8 (PHQ-8), and Patient Health Questionnaire-9 (PHQ-9) for detecting major depression: protocol for a systematic review and individual patient data meta-analyses. Systematic Reviews, 2014, 3, 124.	2.5	71
428	The Global Burden of Disease 2010 update: keeping mental health in the spotlight. Epidemiology and Psychiatric Sciences, 2014, 23, 255-257.	1.8	3
429	Cost of Spontaneous Intracerebral Hemorrhage in Canada During 1 Decade. Stroke, 2014, 45, 284-286.	1.0	23
430	The diagnosis of depression and its treatment in Canadian primary care practices: an epidemiological study. CMAJ Open, 2014, 2, E337-E342.	1.1	35
431	Patterns and frequency of the treatment of depression in persons with epilepsy. Epilepsy and Behavior, 2014, 39, 59-64.	0.9	38
432	A comparison of tissue oxygen saturation measurements by 2 different nearâ€infrared spectroscopy monitors in 21 healthy dogs. Journal of Veterinary Emergency and Critical Care, 2014, 24, 536-544.	0.4	8

#	Article	IF	Citations
433	Patient satisfaction with care in epilepsy: How much do we know?. Epilepsia, 2014, 55, 448-455.	2.6	14
434	Systematic review and assessment of validated case definitions for depression in administrative data. BMC Psychiatry, 2014, 14, 289.	1.1	172
435	A prediction algorithm for first onset of major depression in the general population: development and validation. Journal of Epidemiology and Community Health, 2014, 68, 418-424.	2.0	41
436	Exercise as an add-on strategy for the treatment of major depressive disorder: a systematic review. CNS Spectrums, 2014, 19, 496-508.	0.7	74
437	Antidepressant dose and the risk of deliberate self-harm. Epidemiology and Psychiatric Sciences, 2014, 23, 329-331.	1.8	5
438	Prevalence and risk factors for suicidal ideation in a multiple sclerosis population. Journal of Psychosomatic Research, 2014, 76, 312-316.	1.2	33
439	Depression and painful conditions: patterns of association with health status and health utility ratings in the general population. Quality of Life Research, 2014, 23, 363-371.	1.5	2
440	An overview of the statistical methods reported by studies using the Canadian community health survey. BMC Medical Research Methodology, 2014, 14, 15.	1.4	12
441	Prevalence of neurological conditions across the continuum of care based on interRAI assessments. BMC Health Services Research, 2014, 14, 29.	0.9	16
442	Point prevalence and correlates of depression in a national community sample with multiple sclerosis. General Hospital Psychiatry, 2014, 36, 352-354.	1.2	25
443	An all-GaN differential driver for a 60 V GaN-based power amplifier with 1 GHz switching frequency. , 2014, , .		6
444	How Canadian Service Providers Understand, and Incorporate, Biomedical Knowledge of HIV into their Prevention Work and their Own Sexual Practices. AIDS Research and Human Retroviruses, 2014, 30, A275-A275.	0.5	0
445	DEVELOPMENT AND VALIDATION OF A PREDICTION ALGORITHM FOR USE BY HEALTH PROFESSIONALS IN PREDICTION OF RECURRENCE OF MAJOR DEPRESSION. Depression and Anxiety, 2014, 31, 451-457.	2.0	30
446	Evidence-based guideline: Assessment and management of psychiatric disorders in individuals with MS. Neurology, 2014, 82, 174-181.	1.5	189
447	Validating screening tools for depression in epilepsy. Epilepsia, 2014, 55, 1642-1650.	2.6	59
448	RECURRENCE OF MAJOR DEPRESSIVE EPISODES IS STRONGLY DEPENDENT ON THE NUMBER OF PREVIOUS EPISODES. Depression and Anxiety, 2014, 31, 72-76.	2.0	35
449	The Expression Pattern of a Cav3-Kv4 Complex Differentially Regulates Spike Output in Cerebellar Granule Cells. Journal of Neuroscience, 2014, 34, 8800-8812.	1.7	28
450	Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2014, 384, 1005-1070.	6.3	786

#	Article	IF	CITATIONS
451	Opening Minds Stigma Scale for Health Care Providers (OMS-HC): Examination of psychometric properties and responsiveness. BMC Psychiatry, 2014, 14, 120.	1.1	122
452	Global, regional, and national levels and causes of maternal mortality during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2014, 384, 980-1004.	6.3	1,230
453	Changing Perceptions of Mental Health in Canada. Canadian Journal of Psychiatry, 2014, 59, 591-596.	0.9	7
454	Key Ingredients of Anti-Stigma Programs for Health Care Providers: A Data Synthesis of Evaluative Studies. Canadian Journal of Psychiatry, 2014, 59, 19-26.	0.9	173
455	Antidepressant Use in Canada Has Stopped Increasing. Canadian Journal of Psychiatry, 2014, 59, 609-614.	0.9	11
456	Opening Minds in Canada: Background and Rationale. Canadian Journal of Psychiatry, 2014, 59, 8-12.	0.9	56
457	Opening Minds in Canada: Targeting Change. Canadian Journal of Psychiatry, 2014, 59, 13-18.	0.9	94
458	Important Messages for Clinical Care and Health Policy on Suicide. Canadian Journal of Psychiatry, 2014, 59, 509-510.	0.9	0
459	Reviews and Perspectives. Canadian Journal of Psychiatry, 2014, 59, 1-2.	0.9	5
460	Delicate Considerations and Blunt Instruments. Canadian Journal of Psychiatry, 2014, 59, 117-117.	0.9	1
461	Support, Patience, and Expectancy: Therapeutic Options Alongside Intensified Treatments for Depression?. Canadian Journal of Psychiatry, 2014, 59, 347-348.	0.9	1
462	Stigma in Canada: Results from a Rapid Response Survey. Canadian Journal of Psychiatry, 2014, 59, 27-33.	0.9	51
463	P3-285: ACUTE CARE TRANSITIONS AND OUTCOMES AMONG ASSISTED LIVING RESIDENTS WITH AND WITHOUT DEMENTIA. , 2014, 10, P735-P736.		1
464	Patterns and Determinants of Dementia Pharmacotherapy in a Population-Based Cohort of Home Care Clients. Drugs and Aging, 2013, 30, 569-585.	1.3	14
465	Quetiapine Fumarate for the Treatment of Multiple Sclerosis: Focus on Myelin Repair. CNS Neuroscience and Therapeutics, 2013, 19, 737-744.	1.9	44
466	Childhood and adult stressors and major depression risk: interpreting interactions with the sufficient-component cause model. Social Psychiatry and Psychiatric Epidemiology, 2013, 48, 927-933.	1.6	16
467	Mental comorbidity and multiple sclerosis: validating administrative data to support population-based surveillance. BMC Neurology, 2013, 13, 16.	0.8	122
468	Major depression epidemiology from a diathesis-stress conceptualization. BMC Psychiatry, 2013, 13, 19.	1.1	30

#	Article	IF	CITATIONS
469	Prevalence and incidence of ischemic heart disease in multiple sclerosis: A population-based validation study. Multiple Sclerosis and Related Disorders, 2013, 2, 355-361.	0.9	34
470	Development and validation of prediction algorithms for major depressive episode in the general population. Journal of Affective Disorders, 2013, 151, 39-45.	2.0	33
471	The case for vitamin D supplementation in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2013, 2, 281-306.	0.9	13
472	The Pharmacoepidemiology of Selective Serotonin Reuptake Inhibitors for Children and Adolescents in Canada from 2005 to 2009: A Database Analysis. Paediatric Drugs, 2013, 15, 319-327.	1.3	27
473	Bistability in Purkinje neurons: Ups and downs in cerebellar research. Neural Networks, 2013, 47, 18-31.	3.3	40
474	Depression in epilepsy. Neurology, 2013, 80, 590-599.	1.5	308
475	Stress and development of depression and heavy drinking in adulthood: moderating effects of childhood trauma. Social Psychiatry and Psychiatric Epidemiology, 2013, 48, 265-274.	1.6	33
476	RECURRENCE RISK IN MAJOR DEPRESSION. Depression and Anxiety, 2013, 30, 1-4.	2.0	16
477	Depression and suicide ideation in late adolescence and early adulthood are an outcome of child hunger. Journal of Affective Disorders, 2013, 150, 123-129.	2.0	147
478	GBD 2010 country results: a global public good. Lancet, The, 2013, 381, 965-970.	6.3	36
479	Global variation in the prevalence and incidence of major depressive disorder: a systematic review of the epidemiological literature. Psychological Medicine, 2013, 43, 471-481.	2.7	860
480	The Ca _v 3–K _v 4 Complex Acts as a Calcium Sensor to Maintain Inhibitory Charge Transfer during Extracellular Calcium Fluctuations. Journal of Neuroscience, 2013, 33, 7811-7824.	1.7	44
481	The Utility of Administrative Data for Surveillance of Comorbidity in Multiple Sclerosis: A Validation Study. Neuroepidemiology, 2013, 40, 85-92.	1.1	62
482	Relationship Between Relapse and Hospitalization in First-Episode Psychosis. Psychiatric Services, 2013, 64, 796-799.	1.1	38
483	Modeling interactions between voltage-gated Ca ²⁺ channels and KCa1.1 channels. Channels, 2013, 7, 524-529.	1.5	15
484	Receiving Workplace Mental Health Accommodations and the Outcome of Mental Disorders in Employees With a Depressive and/or Anxiety Disorder. Journal of Occupational and Environmental Medicine, 2013, 55, 1293-1299.	0.9	25
485	Work Reintegration for Veterans With Mental Disorders: A Systematic Literature Review to Inform Research. Physical Therapy, 2013, 93, 1163-1174.	1.1	21
486	Burden of Depressive Disorders by Country, Sex, Age, and Year: Findings from the Global Burden of Disease Study 2010. PLoS Medicine, 2013, 10, e1001547.	3.9	2,377

#	Article	IF	Citations
487	High Positive Psychiatrie Screening Rates in an Urban Homeless Population. Canadian Journal of Psychiatry, 2013, 58, 353-360.	0.9	8
488	Diagnostic data for neurological conditions in interRAI assessments in home care, nursing home and mental health care settings: a validity study. BMC Health Services Research, 2013, 13, 457.	0.9	60
489	The Incidence and Prevalence of Multiple Sclerosis in Nova Scotia, Canada. Canadian Journal of Neurological Sciences, 2013, 40, 824-831.	0.3	53
490	Ethical and Legal Considerations for Canadian Registries. Canadian Journal of Neurological Sciences, 2013, 40, S5-S22.	0.3	8
491	Reducing the stigma of mental illness in undergraduate medical education: a randomized controlled trial. BMC Medical Education, 2013, 13, 141.	1.0	112
492	Low Voltage Activation of KCa1.1 Current by Cav3-KCa1.1 Complexes. PLoS ONE, 2013, 8, e61844.	1.1	48
493	The Reliability and Sensitivity of the National Institutes of Health Stroke Scale for Spontaneous Intracerebral Hemorrhage in an Uncontrolled Setting. PLoS ONE, 2013, 8, e84702.	1.1	12
494	Recreational Physical Activity Ameliorates Some of the Negative Impact of Major Depression on Health-Related Quality of Life. Frontiers in Psychiatry, 2013, 4, 22.	1.3	9
495	Signal processing by T-type calcium channel interactions in the cerebellum. Frontiers in Cellular Neuroscience, 2013, 7, 230.	1.8	20
496	The Epidemiological Modelling of Major Depressive Disorder: Application for the Global Burden of Disease Study 2010. PLoS ONE, 2013, 8, e69637.	1.1	242
497	Mental Health Practice and Attitudes of Family Physicians Can Be Changed!. , 2013, 17, 14-17.		37
498	Depression as a predictor of occupational transition in a multiple sclerosis cohort. Functional Neurology, 2013, 28, 275-80.	1.3	7
499	Review: depression is associated with an increased risk of stroke in adults. Evidence-Based Mental Health, 2012, 15, 6-6.	2.2	1
500	Rethinking recommendations for screening for depression in primary care. Cmaj, 2012, 184, 413-418.	0.9	184
501	Managing pathologic aggression in people with psychotic disorders. Journal of Psychiatry and Neuroscience, 2012, 37, E3-E4.	1.4	3
502	Intermediate conductance calcium-activated potassium channels modulate summation of parallel fiber input in cerebellar Purkinje cells. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2601-2606.	3.3	85
503	A Population-based Longitudinal Study on Work Environmental Factors and the Risk of Major Depressive Disorder. American Journal of Epidemiology, 2012, 176, 52-59.	1.6	95
504	The Multiple Sclerosis Depression Rating Scale. Expert Review of Neurotherapeutics, 2012, 12, 1053-1055.	1.4	3

#	Article	IF	CITATIONS
505	Evaluation of the 9–Item Patient Health Questionnaire (PHQ–9) as an Assessment Instrument for Symptoms of Depression in Patients with Multiple Sclerosis. Postgraduate Medicine, 2012, 124, 69-77.	0.9	62
506	Utilization of General and Specialized Cardiac Care by People With Schizophrenia. Psychiatric Services, 2012, 63, 237-242.	1.1	13
507	Re-rethinking the article by Thombs and colleagues: Figure 1:. Cmaj, 2012, 184, 438.2-439.	0.9	2
508	Predictors of 1-year outcomes of major depressive disorder among individuals with a lifetime diagnosis: a population-based study. Psychological Medicine, 2012, 42, 327-334.	2.7	22
509	Rising prevalence of vascular comorbidities in multiple sclerosis: validation of administrative definitions for diabetes, hypertension, and hyperlipidemia. Multiple Sclerosis Journal, 2012, 18, 1310-1319.	1.4	109
510	$\hat{Al^2}$ neurotoxicity depends on interactions between copper ions, prion protein, and <i>N</i> -methyl- <scp>d</scp> -aspartate receptors. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 1737-1742.	3.3	209
511	Business mergers and acquisitions and the risk of mental disorders: a population-based study. Occupational and Environmental Medicine, 2012, 69, 569-573.	1.3	9
512	Disability in a Community Population with MS with and without Mental Disorders. International Journal of Psychiatry in Medicine, 2012, 43, 51-65.	0.8	4
513	Substantial Changes in Prescription Recommendations for Bipolar Disorder in Canada: 2002–2010. Canadian Journal of Psychiatry, 2012, 57, 263-268.	0.9	9
514	Les recommandations thérapeutiques relatives aux effets secondaires extrapyramidaux associés à l'utilisation d'antipsychotiques de deuxième génération chez les enfants et les adolescents. Paediatrics and Child Health, 2012, 17, 22B-30B.	0.3	4
515	Prevalence Inflation. Canadian Journal of Psychiatry, 2012, 57, 649-650.	0.9	0
516	A Review of Pharmacoepidemiologic Studies of Antipsychotic Use in Children and Adolescents. Canadian Journal of Psychiatry, 2012, 57, 717-721.	0.9	60
517	A Dynamic View of Depressive Symptoms and Neurocognitive Change Among Patients With Coronary Artery Disease. Archives of General Psychiatry, 2012, 69, 244.	13.8	29
518	Is Mental Health in the Canadian Population Changing over Time?. Canadian Journal of Psychiatry, 2012, 57, 324-331.	0.9	37
519	Perceived Discrimination among People with Self-Reported Emotional, Psychological, or Psychiatric Conditions in a Population-Based Sample of Canadians Reporting a Disability. Canadian Journal of Psychiatry, 2012, 57, 102-110.	0.9	11
520	Health Status, Stress and Life Satisfaction in a Community Population with MS. Canadian Journal of Neurological Sciences, 2012, 39, 206-212.	0.3	9
521	Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, The, 2012, 380, 2197-2223.	6.3	7,061
522	Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, The, 2012, 380, 2163-2196.	6.3	6,376

#	Article	IF	CITATIONS
523	Patterns of disability, care needs, and quality of life of people with Parkinson's disease in a general population sample. Parkinsonism and Related Disorders, 2012, 18, 828-832.	1.1	29
524	ALCOHOL CONSUMPTION AND MAJOR DEPRESSION IN THE GENERAL POPULATION: THE CRITICAL IMPORTANCE OF DEPENDENCE. Depression and Anxiety, 2012, 29, 1058-1064.	2.0	55
525	Effectiveness of contact-based education for reducing mental illness-related stigma in pharmacy students. BMC Medical Education, 2012, 12, 120.	1.0	132
526	Comparing frailty measures in their ability to predict adverse outcome among older residents of assisted living. BMC Geriatrics, 2012, 12, 56.	1.1	93
527	The development and psychometric properties of a new scale to measure mental illness related stigma by health care providers: The opening minds scale for Health Care Providers (OMS-HC). BMC Psychiatry, 2012, 12, 62.	1.1	151
528	Synthesis through Simulation: Insights on the Epidemiology of Mood and Anxiety Disorders in Canada. Canadian Journal of Psychiatry, 2012, 57, 765-771.	0.9	4
529	Influence of somatic symptoms on PHQ-9 depression scores among patients with systemic sclerosis compared to a healthy general population sample. Arthritis Care and Research, 2012, 64, n/a-n/a.	1.5	22
530	Recall of recent and more remote depressive episodes in a prospective cohort study. Social Psychiatry and Psychiatric Epidemiology, 2012, 47, 691-696.	1.6	46
531	Epilepsy is associated with unmet health care needs compared to the general population despite higher health resource utilization—A Canadian populationâ€based study. Epilepsia, 2012, 53, 291-300.	2.6	34
532	Depressive episode characteristics and subsequent recurrence risk. Journal of Affective Disorders, 2012, 140, 277-284.	2.0	22
533	A Populationâ€Based Longitudinal Community Study of Major Depression and Migraine. Headache, 2012, 52, 422-432.	1.8	65
534	Persistent heavy smoking as risk factor for major depression (MD) incidence – Evidence from a longitudinal Canadian cohort of the National Population Health Survey. Journal of Psychiatric Research, 2012, 46, 436-443.	1.5	46
535	Three job-related stress models and depression: a population-based study. Social Psychiatry and Psychiatric Epidemiology, 2012, 47, 185-193.	1.6	55
536	Perceived Met and Unmet Health-Care Needs in a Community Population with Multiple Sclerosis. International Journal of MS Care, 2012, 14, 2-8.	0.4	34
537	The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and select comorbid medical conditions. Annals of Clinical Psychiatry, 2012, 24, 91-109.	0.6	56
538	Predictors of long-term prognosis of depression. Cmaj, 2011, 183, 1969-1976.	0.9	81
539	Metabolic and Neurological Complications of Second-Generation Antipsychotic Use in Children. Drug Safety, 2011, 34, 651-668.	1.4	117
540	Diabetes, cardiovascular disease, and health care use in people with and without schizophrenia. European Psychiatry, 2011, 26, 327-332.	0.1	17

#	Article	IF	Citations
541	Evidence-based recommendations for monitoring safety of second-generation antipsychotics in children and youth. Paediatrics and Child Health, 2011, 16, 581-589.	0.3	116
542	Perceived Needs for and Use of Workplace Accommodations by Individuals With a Depressive and/or Anxiety Disorder. Journal of Occupational and Environmental Medicine, 2011, 53, 1268-1272.	0.9	42
543	Conceptualizing Excessive Behaviour Syndromes: A Systematic Review. Current Psychiatry Reviews, 2011, 7, 138-151.	0.9	32
544	A Quantitative Analysis of Suspected Environmental Causes of MS. Canadian Journal of Neurological Sciences, 2011, 38, 98-105.	0.3	46
545	Mortality Associated with Major Depression in a Canadian Community Cohort. Canadian Journal of Psychiatry, 2011, 56, 658-666.	0.9	18
546	The Pharmacoepidemiology of Antipsychotics for Adults with Schizophrenia in Canada, 2005 to 2009. Canadian Journal of Psychiatry, 2011, 56, 630-634.	0.9	9
547	Management recommendations for metabolic complications associated with second-generation antipsychotic use in children and youth. Paediatrics and Child Health, 2011, , .	0.3	16
548	Treatment recommendations for extrapyramidal side effects associated with second-generation antipsychotic use in children and youth. Paediatrics and Child Health, 2011, 16, 590-598.	0.3	42
549	Distinct roles for <i>I</i> _T and <i>I</i> _H in controlling the frequency and timing of rebound spike responses. Journal of Physiology, 2011, 589, 5391-5413.	1.3	49
550	The association between antidepressant use and depression eight years later: A national cohort study. Journal of Psychiatric Research, 2011, 45, 1012-1018.	1.5	5
551	Clinical effectiveness, construct and assessment. Journal of Affective Disorders, 2011, 132, S3-S8.	2.0	3
552	Weight gain in relation to major depression and antidepressant medication use. Journal of Affective Disorders, 2011, 134, 288-293.	2.0	36
553	Associations between mammographic density and serum and dietary cholesterol. Breast Cancer Research and Treatment, 2011, 125, 181-189.	1.1	25
554	Operationalizing frailty among older residents of assisted living facilities. BMC Geriatrics, 2011, 11, 23.	1.1	40
555	A Prospective Single-arm Open-label Study of Baclofen and Bupropion SR Combination Therapy for Smoking Cessation. Addictive Disorders and Their Treatment, 2011, 10, 101-104.	0.5	2
556	Major Depression Is a Risk Factor for Shorter Time to First Cigarette Irrespective of the Number of Cigarettes Smoked Per Day: Evidence From a National Population Health Survey. Nicotine and Tobacco Research, 2011, 13, 1059-1067.	1.4	22
557	The Pharmacoepidemiology of Antipsychotic Medications for Canadian Children and Adolescents: 2005–2009. Journal of Child and Adolescent Psychopharmacology, 2011, 21, 537-543.	0.7	79
558	Re: "Job Strain and the Risk of Depression: Is Reporting Biased?". American Journal of Epidemiology, 2011, 174, 125-125.	1.6	9

#	Article	IF	Citations
559	Treatment recommendations for extrapyramidal side effects associated with second-generation antipsychotic use in children and youth. Paediatrics and Child Health, 2011, 16, 590-8.	0.3	16
560	Prevalence of Mental Disorders in a Canadian Household Population with Dementia. Canadian Journal of Neurological Sciences, 2010, 37, 186-194.	0.3	11
561	Workplace Characteristics, Depression, and Health-Related Presenteeism in a General Population Sample. Journal of Occupational and Environmental Medicine, 2010, 52, 836-842.	0.9	71
562	Pharmacoepidemiology of Benzodiazepine and Sedative-Hypnotic Use in a Canadian General Population Cohort during 12 Years of Follow-up. Canadian Journal of Psychiatry, 2010, 55, 792-799.	0.9	10
563	Predictors of the Longitudinal Course of Major Depression in a Canadian Population Sample. Canadian Journal of Psychiatry, 2010, 55, 669-676.	0.9	41
564	The Prevalence of Mental Disorders in the Working Population over the Period of Global Economic Crisis. Canadian Journal of Psychiatry, 2010, 55, 598-605.	0.9	76
565	Frequency of Antidepressant Use in Relation to Recent and Past Major Depressive Episodes. Canadian Journal of Psychiatry, 2010, 55, 532-535.	0.9	8
566	Major Depression and Injury Risk. Canadian Journal of Psychiatry, 2010, 55, 313-318.	0.9	33
567	Non-adherence with psychotropic medications in the general population. Social Psychiatry and Psychiatric Epidemiology, 2010, 45, 47-56.	1.6	101
568	Use of complementary and alternative medicine by those with a chronic disease and the general population - results of a national population based survey. BMC Complementary and Alternative Medicine, 2010, 10, 58.	3.7	134
569	Problems encountered with the use of simulation in an attempt to enhance interpretation of a secondary data source in epidemiologic mental health research. BMC Research Notes, 2010, 3, 231.	0.6	2
570	The incidence of major depression in Canada: The National Population Health Survey. Journal of Affective Disorders, 2010, 123, 158-163.	2.0	36
571	Simulation studies of age-specific lifetime major depression prevalence. BMC Psychiatry, 2010, 10, 85.	1.1	27
572	Health status and healthâ€related behaviors in epilepsy compared to other chronic conditions—A national populationâ€based study. Epilepsia, 2010, 51, 853-861.	2.6	94
573	Regulation of neuronal activity by Cav3-Kv4 channel signaling complexes. Nature Neuroscience, 2010, 13, 333-337.	7.1	162
574	Challenges in screening for depression in multiple sclerosis. Multiple Sclerosis Journal, 2010, 16, 1406-1411.	1.4	29
575	Letter to the Editor: Context dependency of major depression. Psychological Medicine, 2010, 40, 1757-1758.	2.7	2
576	Prevalence of cardiovascular risk factors and disease in people with schizophrenia: A population-based study. Schizophrenia Research, 2010, 117, 75-82.	1.1	162

#	Article	IF	Citations
577	Reciprocal Effects of Social Support in Major Depression Epidemiology. Clinical Practice and Epidemiology in Mental Health, 2010, 6, 126-131.	0.6	35
578	Reciprocal Effects of Social Support in Major Depression Epidemiology. Clinical Practice and Epidemiology in Mental Health, 2010, 1, 126-131.	0.6	0
579	Patterns of benzodiazepine use in a Canadian population sample. Epidemiologia E Psichiatria Sociale, 2009, 18, 248-254.	1.0	20
580	Major Depression, Antidepressant Medication and the Risk of Obesity. Psychotherapy and Psychosomatics, 2009, 78, 182-186.	4.0	45
581	The effect of major depression on participation in preventive health care activities. BMC Public Health, 2009, 9, 87.	1.2	19
582	Major depression and health-related quality of life in Parkinson's disease. General Hospital Psychiatry, 2009, 31, 334-340.	1.2	16
583	A longitudinal community study of major depression and physical activity. General Hospital Psychiatry, 2009, 31, 571-575.	1.2	55
584	Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults Journal of Affective Disorders, 2009, 117, S44-S53.	2.0	175
585	Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults Journal of Affective Disorders, 2009, 117, S54-S64.	2.0	91
586	Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults Journal of Affective Disorders, 2009, 117, S26-S43.	2.0	357
587	Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. II. Psychotherapy alone or in combination with antidepressant medication. Journal of Affective Disorders, 2009, 117, S15-S25.	2.0	154
588	Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. Journal of Affective Disorders, 2009, 117, S1-S2.	2.0	192
589	Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical Guidelines for the Management of Major Depressive Disorder in Adults. I. Classification, Burden and Principles of Management. Journal of Affective Disorders, 2009, 117, S5-S14.	2.0	128
590	The relationship between major depression and marital disruption is bidirectional. Depression and Anxiety, 2009, 26, 1172-1177.	2.0	113
591	Has †lifetime prevalence' reached the end of its life? An examination of the concept. International Journal of Methods in Psychiatric Research, 2009, 18, 221-228.	1.1	59
592	A population-based study on ways of dealing with daily stress: comparisons among individuals with mental disorders, with long-term general medical conditions and healthy people. Social Psychiatry and Psychiatric Epidemiology, 2009, 44, 666-674.	1.6	14
593	Accumulation of major depressive episodes over time in a prospective study indicates that retrospectively assessed lifetime prevalence estimates are too low. BMC Psychiatry, 2009, 9, 19.	1.1	77
594	Allergies and major depression: a longitudinal community study. BioPsychoSocial Medicine, 2009, 3, 3.	0.9	13

#	Article	IF	Citations
595	Designing a knowledge transfer and exchange strategy for the Alberta Depression Initiative: contributions of qualitative research with key stakeholders. International Journal of Mental Health Systems, 2009, 3, 11.	1.1	17
596	Longitudinal epidemiology of major depression as assessed by the Brief Patient Health Questionnaire (PHQ-9). Comprehensive Psychiatry, 2009, 50, 26-33.	1.5	54
597	Suicide. Lancet, The, 2009, 373, 1372-1381.	6.3	1,519
598	Prevalence of cardiovascular disease in people with diabetes with and without schizophrenia: a population-based cohort study. Canadian Journal of Diabetes, 2009, 33, 203.	0.4	0
599	Major Depression as a Risk Factor for High Blood Pressure: Epidemiologic Evidence From a National Longitudinal Study. Psychosomatic Medicine, 2009, 71, 273-279.	1.3	121
600	Population-Based Service Planning for Implementation of MBCT: Linking Epidemiologic Data to Practice. Psychiatric Services, 2009, 60, 1540-1542.	1.1	15
601	Disability Payments for Persons With Severe Mental Illness in Alberta, Canada. Psychiatric Services, 2009, 60, 686-688.	1.1	0
602	Cigarette Smoking, Stages of Change, and Major Depression in the Canadian Population. Canadian Journal of Psychiatry, 2009, 54, 204-208.	0.9	33
603	Re: The Bipolar Spectrum—A Bridge Too Far?. Canadian Journal of Psychiatry, 2009, 54, 348-349.	0.9	0
604	Prospective Evaluation of the Effect of Major Depression on Working Status in a Population Sample. Canadian Journal of Psychiatry, 2009, 54, 841-845.	0.9	20
605	Antidepressant Treatment for Major Depression in Multiple Sclerosis. International Journal of MS Care, 2009, 11, 174-179.	0.4	10
606	The relationship between body mass index and mental health. Social Psychiatry and Psychiatric Epidemiology, 2008, 43, 63-71.	1.6	61
607	Non-remission of depression in the general population as assessed by the HAMD-7 scale. Depression and Anxiety, 2008, 25, 393-397.	2.0	3
608	Potentially inappropriate management of depressive symptoms among Ontario home care clients. International Journal of Geriatric Psychiatry, 2008, 23, 650-659.	1.3	17
609	Comorbidity of Migraine and Psychiatric Disorders—A National Populationâ€Based Study. Headache, 2008, 48, 501-516.	1.8	281
610	The happy docs study: a Canadian Association of Internes and Residents well-being survey examining resident physician health and satisfaction within and outside of residency training in Canada. BMC Research Notes, 2008, 1, 105.	0.6	59
611	Major depression as a risk factor for chronic disease incidence: longitudinal analyses in a general population cohort. General Hospital Psychiatry, 2008, 30, 407-413.	1.2	207
612	Sensitization: The sine qua non of the depressive disorders?. Medical Hypotheses, 2008, 71, 872-875.	0.8	11

#	Article	IF	CITATIONS
613	The prevalence and management of current daily pain among older home care clients \hat{a}^{-} . Pain, 2008, 138, 208-216.	2.0	97
614	Still no evidence that benzodiazepines cause depression. International Journal of Psychiatry in Clinical Practice, 2008, 12, 85-88.	1.2	2
615	Anti-depressant use in association with interferon and glatiramer acetate treatment in multiple sclerosis. Multiple Sclerosis Journal, 2008, 14, 406-411.	1.4	24
616	Lifestyle Characteristics of Psychiatric Outpatients. Canadian Journal of Psychiatry, 2008, 53, 260-266.	0.9	42
617	The Bipolar Spectrum—A Bridge Too Far?. Canadian Journal of Psychiatry, 2008, 53, 762-768.	0.9	24
618	The Evolving Understanding of Major Depression Epidemiology: Implications for Practice and Policy. Canadian Journal of Psychiatry, 2008, 53, 689-695.	0.9	14
619	Major Depression Prevalence is Very High, but the Syndrome is a Poor Proxy for Community Populations' Clinical Treatment Needs. Canadian Journal of Psychiatry, 2008, 53, 411-419.	0.9	44
620	Confounding by severity and indication in observational studies of antidepressant effectiveness. Journal of Population Therapeutics and Clinical Pharmacology, 2008, 15, e367-71.	1.9	6
621	Mood and anxiety disorders, the association with presenteeism in employed members of a general population sample. Epidemiologia E Psichiatria Sociale, 2007, 16, 231-237.	1.0	26
622	Affective Disorders in Motor Neuron Disease: A Population-Based Study. Neuroepidemiology, 2007, 28, 1-7.	1.1	8
623	Incidence of Multiple Sclerosis among First Nations People in Alberta, Canada. Neuroepidemiology, 2007, 28, 21-27.	1.1	18
624	Firing Dynamics of Cerebellar Purkinje Cells. Journal of Neurophysiology, 2007, 98, 278-294.	0.9	83
625	Frequency and Adequacy of Depression Treatment in a Canadian Population Sample. Canadian Journal of Psychiatry, 2007, 52, 780-789.	0.9	20
626	Self-Reported Allergies and Their Relationship to Several Axis I Disorders in a Community Sample. International Journal of Psychiatry in Medicine, 2007, 37, 11-22.	0.8	76
627	Disease Management for Depression in an Ms Clinic. International Journal of Psychiatry in Medicine, 2007, 37, 459-473.	0.8	19
628	Association of Mood, Anxiety, and Substance Use Disorders With Occupational Status and Disability in a Community Sample. Psychiatric Services, 2007, 58, 659-667.	1.1	27
629	Prevalence of Multiple Sclerosis in First Nations People of Alberta. Canadian Journal of Neurological Sciences, 2007, 34, 175-180.	0.3	26
630	Perceived Effectiveness of Mental Health Care Provided by Primary-Care Physicians and Mental Health Specialists. Psychosomatics, 2007, 48, 123-127.	2.5	19

#	Article	IF	Citations
631	Chronic Obstructive Lung Diseases and Prevalence of Mood, Anxiety, and Substance-Use Disorders in a Large Population Sample. Psychosomatics, 2007, 48, 496-501.	2.5	26
632	Climbing Fiber Discharge Regulates Cerebellar Functions by Controlling the Intrinsic Characteristics of Purkinje Cell Output. Journal of Neurophysiology, 2007, 97, 2590-2604.	0.9	62
633	Re: Effectiveness of Antidepressants. Canadian Journal of Psychiatry, 2007, 52, 750-750.	0.9	1
634	An animated depiction of major depression epidemiology. BMC Psychiatry, 2007, 7, 23.	1.1	17
635	Reasons for antidepressant prescriptions in Canada. Pharmacoepidemiology and Drug Safety, 2007, 16, 746-752.	0.9	47
636	Performance measures for evaluating services for people with a first episode of psychosis. Microbial Biotechnology, 2007, 1, 157-167.	0.9	11
637	Knowledge Transfer and Exchange: Review and Synthesis of the Literature. Milbank Quarterly, 2007, 85, 729-768.	2.1	708
638	Psychiatric Comorbidity in Epilepsy: A Populationâ€Based Analysis. Epilepsia, 2007, 48, 2336-2344.	2.6	859
639	Relapse rates in an early psychosis treatment service. Acta Psychiatrica Scandinavica, 2007, 115, 126-131.	2.2	21
640	Assessment of physical etiologies for mood and anxiety disorders in structured diagnostic interviews. Social Psychiatry and Psychiatric Epidemiology, 2007, 42, 462-466.	1.6	3
641	The usefulness of the EQ-5D in differentiating among persons with major depressive episode and anxiety. Quality of Life Research, 2007, 16, 749-754.	1.5	38
642	Fatigue in multiple sclerosis. , 2007, , 805-818.		2
643	Medication Nonadherence and Subsequent Risk of Hospitalisation and Mortality among Older Adults. Drugs and Aging, 2006, 23, 345-356.	1.3	75
644	Sedative Hypnotic Use in Alberta. Canadian Journal of Psychiatry, 2006, 51, 287-294.	0.9	20
645	Does Almost Everybody Suffer from a Bipolar Disorder?. Canadian Journal of Psychiatry, 2006, 51, 6-8.	0.9	31
646	Descriptive Epidemiology of Major Depression in Canada. Canadian Journal of Psychiatry, 2006, 51, 84-90.	0.9	297
647	Self-Reported Diagnoses of Schizophrenia and Psychotic Disorders May Be Valuable for Monitoring and Surveillance. Canadian Journal of Psychiatry, 2006, 51, 256-259.	0.9	30
648	Serum Monitoring of Antipsychotic Drug Levels during Concomitant Administration of Sertraline and Antipsychotic Medication. Canadian Journal of Psychiatry, 2006, 51, 715-718.	0.9	3

#	Article	IF	CITATIONS
649	Forgetfulness: A Role in Noncompliance with Antidepressant Treatment. Canadian Journal of Psychiatry, 2006, 51, 719-722.	0.9	22
650	Hypnotic use in a population-based sample of over thirty-five thousand interviewed Canadians. Population Health Metrics, 2006, 4, 15.	1.3	31
651	Epidemiological Associations between Gambling Behavior, Substance Use & Mood and Anxiety Disorders. Journal of Gambling Studies, 2006, 22, 275-287.	1.1	140
652	Self-reported thyroid disease and mental disorder prevalence in the general population. General Hospital Psychiatry, 2006, 28, 503-508.	1.2	28
653	Mental disorders in a population sample with musculoskeletal disorders. BMC Musculoskeletal Disorders, 2006, 7, 37.	0.8	75
654	Major depression, fibromyalgia and labour force participation: A population-based cross-sectional study. BMC Musculoskeletal Disorders, 2006, 7, 4.	0.8	64
655	Mental health and related disability among workers: A population-based study. American Journal of Industrial Medicine, 2006, 49, 514-522.	1.0	75
656	Psychiatric Side Effects of Interferon Treatment. Current Drug Safety, 2006, 1, 143-150.	0.3	25
657	A major depression prognosis calculator based on episode duration. Clinical Practice and Epidemiology in Mental Health, 2006, 2, 13.	0.6	37
658	Prevalence of violence against women reported in a rural health region. Canadian Journal of Rural Medicine: the Official Journal of the Society of Rural Physicians of Canada = Journal Canadien De La Médecine Rurale: Le Journal Officiel De La Société De Médecine Rurale Du Canada, 2006, 11, 259-67.	0.2	11
659	Assessment of mental health and illness by telephone survey: experience with an Alberta mental health survey. Chronic Diseases in Canada, 2006, 27, 99-109.	0.9	3
660	Comorbidity of Major Depression and Migraine — A Canadian Population-Based Study. Canadian Journal of Psychiatry, 2005, 50, 832-837.	0.9	54
661	International Dosage Differences in Fluoxetine Clinical Trials. Canadian Journal of Psychiatry, 2005, 50, 31-38.	0.9	6
662	Psychotropic Medication Use in Canada. Canadian Journal of Psychiatry, 2005, 50, 605-613.	0.9	72
663	Antidepressant Pharmacoepidemiology in a General Population Sample. Journal of Clinical Psychopharmacology, 2005, 25, 285-587.	0.7	10
664	Descriptive Epidemiology of Affective Disorders in Multiple Sclerosis. CNS Spectrums, 2005, 10, 365-371.	0.7	24
665	Comorbidity of Major Depression with Substance Use Disorders. Canadian Journal of Psychiatry, 2005, 50, 660-666.	0.9	86
666	Long-Term Medical Conditions and Major Depression: Strength of Association for Specific Conditions in the General Population. Canadian Journal of Psychiatry, 2005, 50, 195-202.	0.9	137

#	Article	IF	Citations
667	Depression in multiple sclerosis. Acta Neurologica Scandinavica, 2005, 111, 209-209.	1.0	11
668	Clinical correlates of CES-D depressive symptom ratings in an MS population. General Hospital Psychiatry, 2005, 27, 439-445.	1.2	35
669	Development of a registry for monitoring psychotropic drug prescriptions: aims, methods and implications for ordinary practice and research. International Journal of Methods in Psychiatric Research, 2005, 14, 151-157.	1.1	7
670	Antidepressant utilization in Canada. Social Psychiatry and Psychiatric Epidemiology, 2005, 40, 799-807.	1.6	74
671	Drug treatment modalities in psychiatric inpatient practice. European Archives of Psychiatry and Clinical Neuroscience, 2005, 255, 136-142.	1.8	10
672	Well-being in residency training: a survey examining resident physician satisfaction both within and outside of residency training and mental health in Alberta. BMC Medical Education, 2005, 5, 21.	1.0	160
673	Describing the longitudinal course of major depression using Markov models: Data integration across three national surveys. Population Health Metrics, 2005, 3, 11.	1.3	11
674	Help-Seeking Behaviours of Individuals with Mood Disorders. Canadian Journal of Psychiatry, 2005, 50, 652-659.	0.9	61
675	Markov models of major depression for linking psychiatric epidemiology to clinical practice. Clinical Practice and Epidemiology in Mental Health, 2005, 1, 2.	0.6	17
676	Modelling major depression epidemiology and assessing the impact of antidepressants on population health. International Review of Psychiatry, 2005, 17, 205-211.	1.4	6
677	From the trenches: views from decision-makers on health services priority setting. Health Services Management Research, 2005, 18, 100-108.	1.0	17
678	The association of depression with disease course in multiple sclerosis. Neurology, 2005, 64, 359-360.	1.5	63
679	Regional variation of multiple sclerosis prevalence in Canada. Multiple Sclerosis Journal, 2005, 11, 516-519.	1.4	122
680	A randomized, openâ€label pilot comparison of gabapentin and bupropion SR for smoking cessation. Nicotine and Tobacco Research, 2005, 7, 809-813.	1.4	26
681	Canadian study finds that antidepressant use has increased in people with major depression over the past decade. Evidence-Based Mental Health, 2005, 8, 26-26.	2.2	0
682	Frontal Brain Asymmetry and Reward Responsiveness: A Source-Localization Study. Psychological Science, 2005, 16, 805-813.	1.8	281
683	The Goldman Consensus statement on depression in multiple sclerosis. Multiple Sclerosis Journal, 2005, 11, 328-337.	1.4	290
684	The relationship between depression and interferon beta-1a therapy in patients with multiple sclerosis. Multiple Sclerosis Journal, 2005, 11, 175-181.	1.4	72

#	Article	IF	CITATIONS
685	Performance Measures for Early Psychosis Treatment Services. Psychiatric Services, 2005, 56, 1570-1582.	1.1	45
686	Interferon- \hat{l}_{\pm} -Induced Depression: When a Randomized Trial Is Not a Randomized Controlled Trial. Psychotherapy and Psychosomatics, 2005, 74, 387-387.	4.0	9
687	Treatment of neuropsychiatric syndromes in multiple sclerosis. Expert Review of Neurotherapeutics, 2005, 5, 413-420.	1.4	4
688	Psychotic disorders in MS: Population-based evidence of an association. Neurology, 2005, 65, 1123-1125.	1.5	106
689	Predictive Value of the CES-D in Detecting Depression Among Candidates for Disease-Modifying Multiple Sclerosis Treatment. Psychosomatics, 2005, 46, 131-134.	2.5	93
690	An analysis of data from two general health surveys found that increased incidence and duration contributed to elevated prevalence of major depression in persons with chronic medical conditions. Journal of Clinical Epidemiology, 2005, 58, 184-189.	2.4	27
691	PMH39 THE USEFULNESS OF THE EQ-5D IN DIFFERENTIATING AMONG PERSONS WITH MAJOR DEPRESSIVE EPISODE AND ANXIETY. Value in Health, 2005, 8, 396.	0.1	0
692	Measurement issues related to the evaluation and monitoring of major depression prevalence in Canada. Chronic Diseases in Canada, 2005, 26, 100-6.	0.9	11
693	Major Depression and Mental Health Care Utilization in Canada: 1994 to 2000. Canadian Journal of Psychiatry, 2004, 49, 303-309.	0.9	57
694	Towards a dynamic description of major depression epidemiology. Epidemiologia E Psichiatria Sociale, 2004, 13, 21-28.	1.0	11
695	The effect of immunomodulatory treatment on multiple sclerosis fatigue. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 1045-1047.	0.9	78
696	Refining Estimates of Major Depression Incidence and Episode Duration in Canada Using a Monte Carlo Markov Model. Medical Decision Making, 2004, 24, 351-358.	1.2	25
697	Off-label and non-classical prescriptions of antipsychotic agents in ordinary in-patient practice. Acta Psychiatrica Scandinavica, 2004, 109, 275-278.	2.2	44
698	Epidemic theory and group violence. Social Psychiatry and Psychiatric Epidemiology, 2004, 39, 853-856.	1.6	32
699	The impact of antidepressant treatment on population health: synthesis of data from two national data sources in Canada. Population Health Metrics, 2004, 2, 9.	1.3	17
700	Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Annals of Neurology, 2004, 55, 756-756.	2.8	156
701	Drug-Induced Depression: A Systematic Review to Inform Clinical Practice. Psychotherapy and Psychosomatics, 2004, 73, 207-215.	4.0	111
702	Adjustment to antidepressant utilization rates to account for depression in remission. Comprehensive Psychiatry, 2004, 45, 268-274.	1.5	14

#	Article	IF	Citations
703	International differences in major depression prevalence: what do they mean?. Journal of Clinical Epidemiology, 2004, 57, 762.	2.4	O
704	Epidemiological theory, decision theory and mental health services research. Social Psychiatry and Psychiatric Epidemiology, 2004, 39, 893-898.	1.6	9
705	The Changing Pattern of Inpatient Antipsychotic Drug Use in Italy. Journal of Clinical Psychopharmacology, 2004, 24, 559-561.	0.7	2
706	Recall bias and major depression lifetime prevalence. Social Psychiatry and Psychiatric Epidemiology, 2003, 38, 290-296.	1.6	108
707	Epidemiology of major depression in a predominantly rural health region. Social Psychiatry and Psychiatric Epidemiology, 2003, 38, 360-365.	1.6	27
708	Priority setting in health authorities: a novel approach to a historical activity. Social Science and Medicine, 2003, 57, 1653-1663.	1.8	68
709	Lifetime patterns of depressive symptoms in the community and among primary care attenders: an application of grade of membership analysis. Journal of Affective Disorders, 2003, 77, 31-39.	2.0	10
710	Irritable bowel syndrome: are incentives useful for improving survey response rates?. Journal of Clinical Epidemiology, 2003, 56, 256-261.	2.4	9
711	International differences in major depression prevalence: What do they mean?. Journal of Clinical Epidemiology, 2003, 56, 711-716.	2.4	34
712	Depressive symptoms in a treated multiple sclerosis cohort. Multiple Sclerosis Journal, 2003, 9, 616-620.	1.4	68
713	Major depression in multiple sclerosis. Neurology, 2003, 61, 1524-1527.	1.5	458
714	Prevention of Depressive Symptoms Through the Use of Distance Technologies. Psychiatric Services, 2003, 54, 396-398.	1.1	57
715	Effect of Depression on Stroke Morbidity and Mortality. Canadian Journal of Psychiatry, 2003, 48, 250-257.	0.9	78
716	Mental Health Services Received by Depressed Persons Who Visited General Practitioners and Family Doctors. Psychiatric Services, 2003, 54, 878-883.	1.1	35
717	Irritable Bowel Syndrome and Health-Related Quality of Life: A Population-Based Study in Calgary, Alberta. Canadian Journal of Gastroenterology & Hepatology, 2003, 17, 259-263.	1.8	50
718	Dr. Fenton and Colleagues Reply. American Journal of Psychiatry, 2003, 160, 189-189.	4.0	3
719	Underuse of Antidepressants. American Journal of Psychiatry, 2003, 160, 189-a-190.	4.0	7
720	Major depressive episodes and diet pills. Expert Opinion on Pharmacotherapy, 2002, 3, 1405-1409.	0.9	2

#	Article	IF	Citations
721	Interferon \hat{I}^21a and depression in secondary progressive MS: Data from the SPECTRIMS Trial. Neurology, 2002, 59, 744-746.	1.5	84
722	Major Depressive Disorder and Health Care Costs in Multiple Sclerosis. International Journal of Psychiatry in Medicine, 2002, 32, 167-178.	0.8	10
723	Double-Blind, Placebo-Controlled Comparison of the Efficacy of Sertraline as Treatment for a Major Depressive Episode in Patients With Remitted Schizophrenia. Journal of Clinical Psychopharmacology, 2002, 22, 20-25.	0.7	54
724	Progress against Major Depression in Canada. Canadian Journal of Psychiatry, 2002, 47, 775-780.	0.9	25
725	The Association of Depressed Affect and Stroke in Institutionalized Canadians. Canadian Journal of Psychiatry, 2002, 47, 791-791.	0.9	0
726	Depression in Multiple Sclerosis Associated with Interferon Beta-1a (Rebif). Canadian Journal of Psychiatry, 2002, 47, 686-686.	0.9	25
727	Treatment-Seeking Rates and Associated Mediating Factors among Individuals with Depression. Canadian Journal of Psychiatry, 2002, 47, 660-665.	0.9	54
728	Major Depression and its Association with Long-Term Medical Conditions. Canadian Journal of Psychiatry, 2002, 47, 149-152.	0.9	50
729	Hopelessness Ratings in Relapsing-Remitting and Secondary Progressive Multiple Sclerosis. International Journal of Psychiatry in Medicine, 2002, 32, 155-165.	0.8	22
730	The Moderating Effects of Coping Strategies on Major Depression in the General Population. Canadian Journal of Psychiatry, 2002, 47, 167-173.	0.9	33
731	Prospective study of frequent heavy alcohol use and the risk of major depression in the canadian general population. Depression and Anxiety, 2002, 15, 42-45.	2.0	61
732	Modeling methods for facilitating decisions in pharmaceutical policy and population therapeutics. Pharmacoepidemiology and Drug Safety, 2002, 11, 165-168.	0.9	7
733	A framework for describing the impact of antidepressant medications on population health status. Pharmacoepidemiology and Drug Safety, 2002, $11,549-559$.	0.9	18
734	Effects of a brief intervention on social support and psychiatric morbidity in breast cancer patients. Psycho-Oncology, 2002, 11, 282-294.	1.0	60
735	Medication use and major depressive syndrome in a community population. Comprehensive Psychiatry, 2001, 42, 124-131.	1.5	31
736	"Diet Pills―and Major Depression in the Canadian Population. Canadian Journal of Psychiatry, 2001, 46, 438-440.	0.9	4
737	Descriptive Epidemiology of a Depressive Syndrome in a Western Canadian Community Population. Canadian Journal of Public Health, 2001, 92, 392-395.	1.1	16
738	Using Databases to Prevent Inpatient Morbidity. Canadian Journal of Psychiatry, 2001, 46, 455-455.	0.9	1

#	Article	IF	CITATIONS
739	A Prospective Study of Sex-Specific Effects of Major Depression on Alcohol Consumption. Canadian Journal of Psychiatry, 2001, 46, 422-425.	0.9	43
740	Perceived work stress and major depression in the Canadian employed population, 20–49 years old Journal of Occupational Health Psychology, 2001, 6, 283-289.	2.3	78
741	Alcohol Consumption and Major Depression: Findings from a Follow-up Study. Canadian Journal of Psychiatry, 2001, 46, 632-638.	0.9	51
742	Alternative Medicine Use by Individuals with Major Depression. Canadian Journal of Psychiatry, 2001, 46, 528-533.	0.9	31
743	Delirium in Psychiatric Inpatients: A Case-Control Study. Canadian Journal of Psychiatry, 2001, 46, 162-166.	0.9	23
744	Long-term medical conditions and major depression in a Canadian population study at waves 1 and 2. Journal of Affective Disorders, 2001, 63, 35-41.	2.0	198
745	Perceived work stress and major depression in the Canadian employed population, 20-49 years old. Journal of Occupational Health Psychology, 2001, 6, 283-9.	2.3	41
746	Interferon \hat{l}^2 -1a and depression in relapsing $\hat{a}\in\hat{l}$ remitting multiple sclerosis: an analysis of depression data from the PRISMS clinical trial. Multiple Sclerosis Journal, 2001, 7, 243-248.	1.4	53
747	Major Depression and Quality of Life in Individuals with Multiple Sclerosis. International Journal of Psychiatry in Medicine, 2000, 30, 309-317.	0.8	90
748	The Predictive Value of Dysgraphia and Constructional Apraxia for Delirium in Psychiatric Inpatients. Canadian Journal of Psychiatry, 2000, 45, 75-78.	0.9	12
749	Major Depression Prevalence in Calgary. Canadian Journal of Psychiatry, 2000, 45, 923-926.	0.9	22
750	Biopsychosocial correlates of lifetime major depression in a multiple sclerosis population. Multiple Sclerosis Journal, 2000, 6, 115-120.	1.4	160
751	Selection bias in studies of major depression using clinical subjects. Journal of Clinical Epidemiology, 2000, 53, 351-357.	2.4	31
752	The Utility of the Transtheoretical Model of Behavior Change for HIV Risk Reduction in Injection Drug Users. Journal of the Association of Nurses in AIDS Care, 2000, 11, 57-66.	0.4	14
753	The specificity of epidemiological correlates of major depression. Comprehensive Psychiatry, 2000, 41, 92-96.	1.5	2
754	Exogenous corticosteroids and major depression in the general population. Journal of Psychosomatic Research, 2000, 49, 447-449.	1.2	35
755	Corticosteroid-Induced Adverse Psychiatric Effects. Drug Safety, 2000, 22, 111-122.	1.4	152
756	Biopsychosocial correlates of lifetime major depression in a multiple sclerosis population. Multiple Sclerosis Journal, 2000, 6, 115-120.	1.4	11

#	Article	IF	CITATIONS
757	Democratizing the Institutions of Policy-making: Democratic Consultation and Participatory Administration. Journal of Canadian Studies, 2000, 35, 221-239.	0.3	27
758	Exogenous corticosteroid exposures are associated with increased recollection of traumatic life events. Journal of Affective Disorders, 1999, 53, 123-128.	2.0	2
759	Antihypertensive medications and depression, an historical perspective., 1999, 8, 355-359.		4
760	Depressive symptoms and disorders, levels of functioning and psychosocial stress: an integrative hypothesis. Medical Hypotheses, 1999, 53, 210-216.	0.8	14
761	Epidemics of violence. Medical Hypotheses, 1999, 53, 217-220.	0.8	9
762	Symptomatic therapies of multiple sclerosis. Biomedicine and Pharmacotherapy, 1999, 53, 371-379.	2.5	11
763	Long-Term Medical Conditions and Major Depression in the Canadian Population. Canadian Journal of Psychiatry, 1999, 44, 151-157.	0.9	88
764	The Reform Party's Re-imagining of the Canadian Nation. Journal of Canadian Studies, 1999, 34, 27-51.	0.3	10
765	Information needs and seeking behaviors of patients with inflammatory bowel disease. Gastroenterology, 1998, 114, A995.	0.6	5
766	Alcohol Consumption and Major Depression in the Canadian Population. Canadian Journal of Psychiatry, 1998, 43, 502-506.	0.9	32
767	Depression in people with first-episode schizophrenia. British Journal of Psychiatry, 1998, 172, 90-92.	1.7	282
768	Drug-Induced Depression. Psychotherapy and Psychosomatics, 1997, 66, 63-73.	4.0	55
769	The Incidence of Delirium in Psychiatric Inpatient Units. Canadian Journal of Psychiatry, 1997, 42, 858-863.	0.9	16
770	Depression in Multiple Sclerosis. Psychotherapy and Psychosomatics, 1997, 66, 286-292.	4.0	89
771	Of Passionate Intensity: Right-Wing Populism and the Reform Party of Canada. Canadian Journal of Sociology, 1997, 22, 132.	0.4	0
772	Risk of suicide attempts after benzodiazepine and/or antidepressant use. Annals of Epidemiology, 1997, 7, 568-574.	0.9	68
773	Course, correlates and predictors of depression in schizophrenia. Schizophrenia Research, 1996, 18, 117.	1.1	0
774	H ₂ Blocker Exposure as a Risk Factor for Depression. Canadian Journal of Psychiatry, 1996, 41, 537-538.	0.9	3

#	Article	IF	Citations
775	New Evidence on Benzodiazepine Use and Falls: The Time Factor. Age and Ageing, 1996, 25, 273-278.	0.7	142
776	Self-Reported Depressive Symptoms following Treatment with Corticosteroids and Sedative-Hypnotics. International Journal of Psychiatry in Medicine, 1996, 26, 15-24.	0.8	39
777	Case—Control Studies of Cardiovascular Medications as Risk Factors for Clinically Diagnosed Depressive Disorders in a Hospitalized Population. Canadian Journal of Psychiatry, 1996, 41, 469-476.	0.9	24
778	Depressive Symptoms Attributable to Medication Exposure in a Medical Inpatient Population. Canadian Journal of Psychiatry, 1996, 41, 651-654.	0.9	2
779	Gender and affect in schizophrenia. Canadian Journal of Psychiatry, 1996, 41, 265-8.	0.9	26
780	Organic Depression Associated with Flunarizine. Canadian Journal of Psychiatry, 1995, 40, 111-112.	0.9	13
781	Self-Reported Depressive Symptoms in Association with Medication Exposures among Medical Inpatients: A Cross-Sectional Study. Canadian Journal of Psychiatry, 1995, 40, 264-269.	0.9	10
782	A Case-Control Study of Corticosteroid Exposure as a Risk Factor for Clinically-Diagnosed Depressive Disorders in a Hospitalized Population. Canadian Journal of Psychiatry, 1995, 40, 396-400.	0.9	8
783	Drug-Induced Depression. Drug Safety, 1994, 10, 203-219.	1.4	18
784	Statistical Heterogeneity and Centre Effects in Clinical Trials of Alprazolam. Canadian Journal of Psychiatry, 1994, 39, 316-317.	0.9	0
785	Neuropsychiatric Adverse Drug Reactions: Passive Reports to Health and Welfare Canada's Adverse Drug Reaction Database (1965-Present). International Journal of Psychiatry in Medicine, 1994, 24, 45-62.	0.8	19
786	Clinical interpretation of the mini-mental state. General Hospital Psychiatry, 1993, 15, 254-259.	1.2	17
787	Delayed Sleep Phase Disorder after Traumatic Brain Injury. Journal of the American Academy of Child and Adolescent Psychiatry, 1992, 31, 100-102.	0.3	63
788	Manic Symptoms Associated with the use of Captopril. Canadian Journal of Psychiatry, 1991, 36, 314-315.	0.9	7
789	Evaluation of the Modified Mini-Mental State Examination in a General Psychiatric Population. Canadian Journal of Psychiatry, 1991, 36, 507-511.	0.9	22
790	The Loss of a Parent during Childhood as a Risk Factor for Depression. Canadian Journal of Psychiatry, 1991, 36, 706-711.	0.9	22
791	Dr. Patten Replies. Canadian Journal of Psychiatry, 1990, 35, 457-457.	0.9	0
792	Propranolol and Depression: Evidence from the Antihypertensive Trials. Canadian Journal of Psychiatry, 1990, 35, 257-259.	0.9	36

SCOTT B. PATTEN

#	Article	IF	CITATIONS
793	Dysgraphia. Canadian Journal of Psychiatry, 1989, 34, 746-746.	0.9	4
794	Organic Mania Induced by Phenytoin: A Case Report*. Canadian Journal of Psychiatry, 1989, 34, 827-828.	0.9	12
795	Pharmacological Management of Refractory Depression. Canadian Journal of Psychiatry, 1989, 34, 451-456.	0.9	6
796	Posttraumatic Stress Disorder and the Treatment of Sexual Abuse. Social Work, 1989, 34, 197-203.	0.6	24
797	Sympatry and Interbreeding of Herring and Glaucous-Winged Gulls in Southeastern Alaska. Condor, 1974, 76, 343-344.	0.7	11